WO2001021634A1 - Derives de benzimidazole et bibliotheques combinatoires contenant ces derives - Google Patents

Derives de benzimidazole et bibliotheques combinatoires contenant ces derives Download PDF

Info

Publication number
WO2001021634A1
WO2001021634A1 PCT/US2000/020942 US0020942W WO0121634A1 WO 2001021634 A1 WO2001021634 A1 WO 2001021634A1 US 0020942 W US0020942 W US 0020942W WO 0121634 A1 WO0121634 A1 WO 0121634A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
group
alkyl
phenyl
hydrogen atom
Prior art date
Application number
PCT/US2000/020942
Other languages
English (en)
Inventor
Hengyuan Lang
Yazhong Pei
Original Assignee
Lion Bioscience Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Bioscience Ag filed Critical Lion Bioscience Ag
Priority to EP00950920A priority Critical patent/EP1214330A1/fr
Publication of WO2001021634A1 publication Critical patent/WO2001021634A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • the present invention relates generally to the synthesis of compounds comprising heterocyclic rings.
  • the invention provides novel benzimidazole derivative compounds as well as novel combinatorial libraries comprised of such compounds.
  • the process of discovering new therapeutically active compounds for a given indication involves the screening of all compounds from available compound collections. From the compounds tested, one or more structures is selected as a promising lead. A large number of related analogs are then synthesized in order to develop a structure-activity relationship and select one or more optimal compounds. With traditional "one-at- a-time" synthesis and biological testing of analogs, this optimization process is long and labor intensive. Adding significant numbers of new structures to the compound collections used in the initial screening step of the discovery and optimization process cannot be accomplished with traditional "one-at-a-time" synthesis methods, except over a time frame of years or even decades.
  • Benzimidazole derivative compounds have been the subject of investigation in a number of different biological areas.
  • benzimidazole derivatives have been used extensively as antihistamines, antiulceratives and against viruses (see Mayer et al., supra and Yeh et al., supra )
  • Benzimidazole derivatives have also been the subject of serial chemical synthesis. See, for example, Yukawa, et al., Bioorg. Med. Chem . Lett . , 7:1267 (1997); Thomas et al., Tetrahedron Lett . , 38:5099 (1997); Rakitin et al., Tetrahedron Lett . , 37:4589 (1996); Ries et al .
  • the present invention satisfies this need and provides related advantages as well.
  • the present invention overcomes the known limitations to classical serial organic synthesis of benzimidazole derivatives, for example, as well as the shortcomings of combinatorial chemistry related to benzimidazole derivatives.
  • the present invention allows for rapid generation of large diverse libraries of complex benzimidazole derivatives as discrete molecules.
  • the present invention can utilize a readily available pool of building blocks that can be incorporated into the various regions of the molecule.
  • the method of making the present invention allows for the use of building blocks that contain a wide range of diverse functionality. Such building blocks can provide combinatorial libraries that consist of large numbers as well as combinatorial libraries that are extremely diverse with respect to the functionality contained within those libraries.
  • the present invention combines the techniques of solid-phase synthesis of benzimidazole derivatives and the general techniques of synthesis of combinatorial libraries to prepare highly diverse new benzimidazole derivative compounds.
  • the present invention relates to novel benzimidazole derivative compounds of the following formula :
  • R 1 to R 8 have the meanings provided herein.
  • the invention further relates to combinatorial libraries containing two or more such compounds, as well as methods of preparing benzimidazole derivative compounds .
  • R 1 corresponds to R 6 of the claimed invention
  • -C(0)NHR 2 corresponds to R 3 of the claimed invention (which can be -C (0) NR n R 12 )
  • R 3 corresponds to R 5 of the claimed invention
  • Figure 1 shows the reaction scheme for the combinatorial synthesis of benzimidazole derivative compounds .
  • the present invention provides compounds and combinatorial libraries of compounds of the formula:
  • R 1 , R 2 , R 3 and R 4 are, independently, a hydrogen atom, halo, hydroxy, protected hydroxy, cyano, x to C 12 alkyl, C 2 to C 12 alkenyl, C 2 to C 12 alkynyl, C : to C 12 substituted alkyl, C 2 to C 12 substituted alkenyl, C 2 to C 12 substituted alkynyl, ⁇ to C 12 alkoxy, C : to C 12 substituted alkoxy, C x to C 12 acyloxy, C : to C 12 acyl, C 3 to C 7 cycloalkyl, C 3 to C 7 substituted cycloalkyl, C 5 to C 7 cycloalkenyl, C 5 to C 7 substituted cycloalkenyl, heterocyclic ring, substituted heterocyclic ring, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, C ⁇ to C 12 heterocycloalky
  • R 5 is a hydrogen atom, C x to C 12 alkyl, C ⁇ to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, C x to C 12 heterocycloalkyl, C ⁇ to C 12 substituted heterocycloalkyl, carboxy, protected carboxy, cyano, protected (monosubstituted) amino, (disubstituted) amino, C ⁇ to C 12 acyl, C 1 to C 12 substituted acyl, C x to C 12 alkoxycarbonyl, C ⁇ to C 12 substituted alkoxycarbonyl, heterocycle, substituted heterocycle, naphthyl, substituted naphthyl, C 3 to C 7 cycloalkyl, C 3 to C 7 substituted cycloalkyl, C 5 to C 7 cycloalkenyl or C 5 to C 7 substituted cycloal
  • R 6 is the formula:
  • W is absent or phenylene, substituted phenylene, C 3 to C 7 cycloalkylene, C 3 to C 7 substituted cycloalkylene, C 5 to C 7 cycloalkenylene, C 5 to C 7 substituted cycloalkenylene, arylene, substituted arylene, heterocyclene, substituted heterocyclene, heteroarylene or substituted heteroarylene; and D, which is directly attached to the nitrogen depicted in the formula, and E, which can be absent, are, independently, C x to C 12 alkylene, C 2 to C 12 alkenylene, C 2 to C 12 alkynylene, C ⁇ to C 12 substituted alkylene, C 2 to C 12 substituted alkenylene, C 2 to C 12 substituted alkynylene, C 3 to C 7 cycloalkylene, C 3 to C 7 substituted cycloalkylene, C 5 to C 7 cycloalkenylene, C 5 to C 7 substituted cycloalkenylene, C
  • R 9 and R 10 are, independently, a hydrogen atom, C : to C 12 alkyl, C 2 to C 12 alkenyl, C 2 to C 12 alkynyl, C x to C 12 substituted alkyl, C 2 to C 12 substituted alkenyl, C 2 to C 12 substituted alkynyl, C ⁇ to C 12 acyl, C x to C 12 substituted acyl, C 3 to C 7 cycloalkyl, C 3 to C 7 substituted cycloalkyl, C 5 to C 7 cycloalkenyl, C 5 to C 7 substituted cycloalkenyl, a heterocyclic ring, substituted heterocyclic ring, heteroaryl, substituted heteroaryl, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, C ⁇ to C 12 heterocycloalkyl, C x to C 12 substituted heterocycloalkyl, C 7 to C 18 phenylalkoxy
  • R 7 and R 8 are, independently, a functionalized resin, a hydrogen atom, C ⁇ to C 12 alkyl, C ⁇ to C 12 substituted alkyl, phenyl, substituted phenyl, heterocycle, substituted heterocycle, C 3 to C 7 cycloalkyl, C 3 to C 7 substituted cycloalkyl, C 5 to C 7 cycloalkenyl, C 5 to C 7 substituted cycloalkenyl, C 2 to C 12 alkenyl, C 2 to C 12 substituted alkenyl, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, C x to C 12 heterocycloalkyl and C 1 to C 12 substituted heterocycloalkyl, C x to C 12 acyl, C ⁇ to C 12 substituted acyl, phenylsulfonyl, substituted phenylsulfonyl, C : to C 10 alkylsulfony
  • R 5 is not methylene
  • R 1 , R 2 , R 3 and R 4 are, independently, a hydrogen atom, halo, C t to C 12 alkyl, C : to C 12 substituted alkyl, carboxy, (I) the formula -C(0)NR n R 12 or (ii) the formula -C(0)R n , wherein R 11 and R 12 are, independently, a hydrogen atom, C x to C 12 alkyl, C x to C 12 substituted alkyl, C 2 to C 12 alkenyl, C 2 to C 12 substituted alkenyl, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, C ⁇ to C 12 heterocycloalkyl, C x to C 12 substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle.
  • R 1 , R 2 , and R 4 are each a hydrogen atom and R 3 is halo, C x to C 12 alkyl, C ⁇ to C 12 substituted alkyl, carboxy, (I) the formula -C(0)NR n R 12 or (ii) the formula -C(0)R n , wherein R 11 and R 12 are, independently, a hydrogen atom, C x to C 12 alkyl, C : to C 12 substituted alkyl, C 2 to C 12 alkenyl, C 2 to C 12 substituted alkenyl, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, x to C 12 heterocycloalkyl, C x to C 12 substituted heterocycloalkyl, heteroaryl, substituted heteroaryl, heterocycle or substituted heterocycle.
  • R 5 is a hydrogen atom, C ⁇ to C 12 alkyl, C x to C 12 substituted alkyl, phenyl, substituted phenyl, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, C x to C 12 heterocycloalkyl, ⁇ to C 12 substituted heterocycloalkyl, heterocycle, substituted heterocycle, C 3 to C 7 cycloalkyl or C 3 to C 7 substituted cycloalkyl.
  • R 6 is the formula:
  • W is absent or phenylene, substituted phenylene, C 3 to C 7 cycloalkylene or C 3 to C 7 substituted cycloalkylene;
  • D and E which can be absent, are C 1 to C 12 alkylene, C x to C 12 substituted alkylene, -NH- and the formula:
  • R 9 and R 10 are, independently, a hydrogen atom, C- L to C 12 alkyl, ⁇ to C 12 substituted alkyl, C 3 to C 7 cycloalkyl, C 3 to C 7 substituted cycloalkyl, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, phenyl or substituted phenyl; and m and n are, independently, 0, 1 or 2.
  • R 8 are each a hydrogen atom.
  • R 6 is methylene
  • R 1 , R 2 and R 4 are each a hydrogen atom
  • R 3 is the formula -C (0) NR n R 12 .
  • R 6 is methylene
  • R 1 , R 2 and R" are each a hydrogen atom
  • R 3 is the formula -C(0)R u , wherein R 11 is a heterocyclic ring or substituted heterocyclic ring, wherein the ring contains at least one nitrogen atom and wherein the nitrogen atom is attached to the carbonyl carbon.
  • R 6 is not methylene
  • R 1 , R 2 and R 4 are each a hydrogen atom and R 3 is the formula -C (0) NR 1:L R 12 , wherein wherein R 11 is a hydrogen atom, methyl, ethyl or benzyl and R 12 is a hydrogen atom, benzyl, 4-methoxyphenyl, 4-phenoxyphenyl, (l-ethyl-2-pyrrolidino)methyl, pyridin-2-ylmethyl,
  • R 5 is 3-phenoxyphenyl, 3-hydroxy-4-methoxyphenyl,
  • R 6 is methylene, ethylidene, ethylene, propylene, pentylene, isopentylidene, 3-aminocarbonylbutylidene, 2-methylthiopropylidene, isobutylidene, phenylmethylene, benzylmethylene, cyclohexylethylidene,
  • R 7 and R 8 are each a hydrogen atom.
  • R 1 , R 2 and R 4 are each a hydrogen atom and R 3 is the formula -C(0)R , wherein R 11 is 1, 3, 3-trimethyl-6-aza-6-bicyclo (3, 2,1) octyl,
  • R 5 is 3-phenoxyphenyl, 3-hydroxy-4-methoxyphenyl, 4-acetamidophenyl, 4-phenoxyphenyl, 4-bromo-2-thienyl, 4-pyridyl, 2-butyl, 4-chloro-3-nitrophenyl, 3-nitrophenyl, 2, 3-dichlorophenyl, 2, 5-difluorophenyl, 5-methyl-2-furyl, 4-chloro-3-fluorophenyl, 2-phenyl-4-imidazolyl, 5-nitro-2-furyl, 4-bromophenyl, 2-norbornen-5-yl, 6-nitropiperonyl, 2-chloro-5-nitrophenyl, 5-hydroxy-2-nitrophenyl, 3-hydroxyphenyl, 3, -difluorophenyl, 4-dimethylaminophenyl, 2-thienyl, 4-cyanophenyl, 3-cyanophenyl, 4-nitrophenyl, 2-fluorophenyl, 4-carboxyphen
  • R 6 is methylene, ethylidene, ethylene, propylene, pentylene, isopentylidene, 3-aminocarbonylbutylidene, 2-methylthiopropylidene, isobutylidene, phenylmethylene, benzylmethylene, cyclohexylethylidene,
  • R 7 and R 8 are each a hydrogen atom.
  • R 1 , R 2 and R 4 are each a hydrogen atom and R 3 is the formula -C (0) NR R 12 , wherein R 11 is a hydrogen atom, methyl, ethyl or benzyl and R 12 is a hydrogen atom, 2- (2-methoxyphenyl) ethyl, (l-ethyl-2-pyrrolidino)methyl, pyridin-2-ymethyl, 2-methyl-5-chlorophenyl, 2- (pyridin-2-yl) ethyl, l-ethyl-2-pyrrolidinylmethyl, 3, 3, 5-trimethylcyclohexyl, 3, 4-methylenedioxyphenyl, 3- (trifluoromethyl) benzyl, pyridin-4-ylmethyl, 6-indazolyl, 2- (ethoxylcarbonyl) ethyl, cyclooctyl, cyclopropyl, benzyl, N,N- (diethylamino)
  • R 5 is phenoxyphenyl, 4-hydroxy-3-methoxyphenyl, 3,4, 5-trimethoxyphenyl, 3-hydroxy-4-methoxyphenyl, 4-acetamidophenyl, 4-phenoxyphenyl, 4-methoxyl-l-naphthyl, 4-bromo-2-thienyl, 4-pyridyl, isopropyl, 2-methylthioethyl, 4-chloro-3-nitrophenyl, 3-nitrophenyl, 4-t-butylphenyl, 2, 3-dichlorophenyl, 3, 5-bis (trifluoromethyl) phenyl, 2, 5-difluorophenyl, 2-quinolyl, 2-chloro-3, 4-dimethoxylphenyl, 5-methyl-2-furyl, 4-chloro-3-fluorophenyl, 2-phenyl-4-imidazolyl, 2- (ethoxycarbonyl) cyclopropyl, 5-nitro-2-furyl, 4-bromoph
  • R 6 methylene, ethylidene, ethylene, propylene, pentylene, isopentylidene, 3-aminocarbonylbutylidene, 2-methylthiopropylidene, isobutylidene, phenylmethylene, benzylmethylene, cyclohexylethylidene,
  • R 7 and R 8 are each a hydrogen atom.
  • R 1 , R 2 and R 4 are each a hydrogen atom and R 3 is the formula -C(0)R , wherein R 11 is
  • R 5 is phenoxyphenyl, 4-hydroxy-3-methoxyphenyl, 3, 4, 5-trimethoxyphenyl, 3-hydroxy-4-methoxyphenyl, 4-acetamidophenyl, 4-phenoxyphenyl, 4-methoxyl-l-naphthyl, 4-bromo-2-thienyl, 4-pyridyl, isopropyl, 2-methylthioethyl, 4-chloro-3-nitrophenyl, 3-nitrophenyl, 4-t-butylphenyl, 2 , 3-dichlorophenyl, 3, 5-bis (trifluoromethyl) phenyl, 2, 5-difluorophenyl, 2-quinolyl, 2-chloro-3, 4-dimethoxylphenyl, 5-methyl-2-furyl, 4-chloro-3-fluorophenyl, 2-phenyl-4-imidazolyl, 2- (ethoxycarbonyl) cyclopropyl, 5-nitro-2-furyl, 4-bro
  • R 6 is methylene, ethylidene, ethylene, propylene, pentylene, isopentylidene, 3-aminocarbonylbutylidene, 2-methylthiopropylidene, isobutylidene, phenylmethylene, benzylmethylene, cyclohexylethylidene, 4-chlorobenzylmethylene, indol-3-ylethylidene, 4-trifluoroacetamidopentylidene, 3-guanidobutylidene, hydroxyethylidene, 2-aminocarbonylpropylidene, isopentylidene, mercaptoethylidene, 4-hydroxybenzylmethylene, 1, 3-phenylene, 1, 4-phenylene, 1, 4- (phenylene) -NH-, 3, 6-dioxaoctylene-NH-, -CH 2 CH 2 NH- or 1, 4- (cyclohexylene)
  • R 7 and R 8 are each a hydrogen atom.
  • R 1 , R 2 , R 4 , R 7 and R 8 are each a hydrogen atom
  • R 3 is the formula -C (0) NR n R 12 , wherein R 11 is a hydrogen atom and R 12 is pyridin-2-ylmethyl or 3,3, 5-trimethylcyclohexyl;
  • R 5 is 4-N,N-dimethylaminophenyl, 5-chloro-2-nitrophenyl, 4-bromo-2-thienyl, 2-butyl, 5-nitro-2-furyl,
  • benzimidazole derivative compounds can be prepared by:
  • step (b) reducing the nitro group of the phenyl compound resulting from step (a) ;
  • step (b) ⁇ coupling the compound resulting from step (b) with an aldehyde of the formula variable group-CHO, resulting in a benzimidazole derivative compound.
  • the first compound having a substituent of the formula -NH-C(O)- variable group-NH 2 is attached to solid support.
  • variable group on the phenyl group in step (a) is a carboxyl .
  • An additional method of the invention provides that the carboxyl group of the phenyl compound resulting from step (a) is coupled with a monosubstituted amine compound, a disubstituted amine compound, a cyclic imino compound or an alcohol, resulting, respectively, in (I) a monosubstituted carboxamido substituent attached to the phenyl compound; (ii) a disubstituted substituent carboxamido attached to the phenyl compound; (iii) a cyclic imino carbonyl substituent attached to the phenyl compound; or (iv) an ester substituent attached to the phenyl compound.
  • the stereochemistry of such chiral centers can independently be in the R or S configuration, or a mixture of the two.
  • the chiral centers can be further designated as R or S or R, S or d, D, 1,L or d, 1, D,L.
  • the suffix "ene” added to any of the described terms means that two parts of the substituent are each connected to two other parts in the compound (unless the substituent contains only one carbon, in which case such carbon is connected to two other parts in the compound, for example, methylene) .
  • C 1 to C 12 alkyl denotes such radicals as methyl, ethyl, n-propyl, isopropyl, n-butyl, iso- butyl, sec-butyl, tert-butyl, amyl, tert-amyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl and the like.
  • Preferred “C ⁇ to C 12 alkyl” groups are methyl, ethyl, iso-butyl, sec-butyl and iso-propyl.
  • C 1 to C 12 alkylene denotes radicals of 1 to 12 carbons connected to two other parts in the compound.
  • C 2 to C 12 alkenyl denotes such radicals as vinyl, allyl, 2-butenyl, 3-butenyl, 2- pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, (as well as octenyl, nonenyl, decenyl, undecenyl, dodecenyl radicals attached at any appropriate carbon position and the like) as well as dienes and trienes of straight and branched chains.
  • C 2 to C 12 alkynyl denotes such radicals as ethanol, propynyl, 2-butynyl, 2-pentynyl, 3- pentynyl, 2- hexynyl, 3-hexynyl, 4-hexynyl, 2-heptynyl, 3-heptynyl, 4- heptynyl, 5-heptynyl (as well as octynyl, nonynyl, decynyl, undecynyl, dodecynyl radicals attached at any appropriate carbon position and the like) as well as di- and tri-ynes of straight and branched chains.
  • ⁇ to C 12 substituted alkyl denote groups are substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, C 3 to C 7 cycloalkyl, phenyl, naphthyl, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, imidazolyl, indolyl, pyrrolidinyl, C 1 to C 12 alkoxy, C : to C 12 acyl, C ⁇ to C 12 acyl,
  • Examples of the above substituted alkyl groups include the 2-oxo-prop-l-yl, 3-oxo-but-l-yl, cyanomethyl, nitromethyl, chloromethyl, hydroxymethyl, tetrahydropyranyloxymethyl, trityloxymethyl, propionyloxymethyl, aminomethyl, carboxymethyl, allyloxycarbonylmethyl, allyloxycarbonylaminomethyl, methoxymethyl, ethoxymethyl, t-butoxymethyl, acetoxymethyl, chloromethyl, bromomethyl, iodomethyl, trifluoromethyl, 6-hydroxyhexyl, 2, -dichloro (n-butyl) , 2-aminopropyl, 1-chloroethyl, 2-chloroethyl, 1- bromoethyl, 2-chloroethyl, 1-fluoroethyl, 2-fluoroethyl, 1- iodoethyl, 2-iodo
  • Examples of the above substituted alkenyl groups include styrenyl, 3-chloro-propen-l-yl, 3-chloro- buten-1-yl, 3-methoxy-propen-2-yl, 3-phenyl-buten-2-yl, l-cyano-buten-3-yl and the like.
  • the geometrical isomerism is not critical, and all geometrical isomers for a given substituted alkenyl can be used.
  • Examples of the above substituted alkynyl groups include phenylacetylen-1-yl, l-phenyl-2-propyn-l- yl and the like.
  • oxo denotes a carbon atom bonded to two additional carbon atoms substituted with an oxygen atom doubly bonded to the carbon atom, thereby forming a ketone moiety.
  • protected oxo denotes a carbon atom bonded to two additional carbon atoms substituted with two alkoxy groups or twice bonded to a substituted diol moiety, thereby forming an acyclic or cyclic ketal moiety.
  • C 1 to C 12 alkoxy denotes groups such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy and like groups. A preferred alkoxy is methoxy.
  • C 1 to C 12 substituted alkoxy means the alkyl portion of the alkoxy can be substituted in the same manner as in relation to C x to C 12 substituted alkyl.
  • C x to C 12 phenylalkoxy as used herein means "C ⁇ to C 12 alkoxy" bonded to a phenyl radical.
  • C 1 to C 12 acyloxy denotes herein groups such as formyloxy, acetoxy, propionyloxy, butyryloxy, pivaloyloxy, pentanoyloxy, hexanoyloxy, heptanoyloxy, octanoyloxy, nonanoyloxy, decanoyloxy, undecanoyloxy, dodecanoyloxy and the like.
  • C 1 to C 12 acyl encompasses groups such as formyl, acetyl, propionyl, butyryl, pentanoyl, pivaloyl, hexanoyl, heptanoyl, octanoyl, nonanoyl, decanoyl, undecanoyl, dodecanoyl, benzoyl and the like.
  • Preferred acyl groups are acetyl and benzoyl.
  • C ⁇ to C 12 substituted acyl denotes the acyl group substituted by one or more, and preferably one or two, halogen, hydroxy, protected hydroxy, oxo, protected oxo, cyclohexyl, naphthyl, amino, protected amino, (monosubstituted) amino, protected
  • the substituted acyl groups may be substituted once or more, and preferably once or twice, with
  • C 1 to C 12 substituted acyl groups include 4-phenylbutyroyl, 3-phenylbutyroyl, 3-phenylpropanoyl, 2- cyclohexanylacetyl, cyclohexanecarbonyl, 2-furanoyl and 3-dimethylaminobenzoyl .
  • C 3 to C 7 cycloalkyl includes the cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl rings.
  • a substituent that can be C 3 to C 7 cycloalkyl can also be "C 5 to C 7 cycloalkyl,” which includes the cyclopentyl, cyclohexyl or cycloheptyl rings.
  • C 3 to C 7 substituted cycloalkyl indicates the above cycloalkyl rings substituted by one or two halogen, hydroxy, protected hydroxy, C 1 to C 10 alkylthio, x to C 10 alkylsulfoxide, C-, to C 10 alkylsulfonyl, C ⁇ to C 10 substituted alkylthio, C x to C 10 substituted alkylsulfoxide, C ⁇ to C 10 substituted alkylsulfonyl, C x to C 12 alkyl, C ⁇ to C 12 alkoxy, C ⁇ to C 12 substituted alkyl, x to C 12 alkoxy, oxo, protected oxo, (monosubstituted) amino, (disubstituted) amino, trifluoromethyl, carboxy, protected carboxy, phenyl, substituted phenyl, phenylthio
  • cycloalkylene means a cycloalkyl, as defined above, where the cycloalkyl radical is bonded at two positions connecting together two separate additional groups.
  • substituted cycloalkylene means a cycloalkylene where the cycloalkyl radical is bonded at two positions connecting together two separate additional groups and further bearing at least one additional substituent.
  • C 5 to C 7 cycloalkenyl indicates a 1,2, or 3-cyclopentenyl ring, a 1,2,3 or 4-cyclohexenyl ring or a 1,2,3,4 or 5-cycloheptenyl ring
  • substituted C 5 to C 7 cycloalkenyl denotes the above C 5 to C 7 cycloalkenyl rings substituted by a C ⁇ to C 12 alkyl radical, halogen, hydroxy, protected hydroxy, ⁇ to C 12 alkoxy, trifluoromethyl, carboxy, protected carboxy, oxo, protected oxo, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, phenyl, substituted phenyl, amino, or protected amino.
  • C 5 to C 7 cycloalkenylene is a cycloalkenyl ring, as defined above, where the cycloalkenyl radical is bonded at two positions connecting together two separate additional groups.
  • Examples of C 5 to C 7 cycloalkenylenes include 1, 3-cyclopentylene and 1, 2-cyclohexylene .
  • substituted C 5 to C 7 cycloalkenylene means a cycloalkenylene further substituted by halogen, hydroxy, protected hydroxy, C ⁇ to C 10 alkylthio, C 1 to C 10 alkylsulfoxide, C ⁇ to C 10 alkylsulfonyl, C x to C 10 substituted alkylthio, C x to C 10 substituted alkylsulfoxide, C x to C 10 substituted alkylsulfonyl, C x to C 12 alkyl, C ⁇ to C 12 alkoxy, C : to C 12 substituted alkyl, C x to C 12 alkoxy, oxo, protected oxo, (monosubstituted) amino, (disubstituted) amino, trifluoromethyl, carboxy, protected carboxy, phenyl, substituted phenyl, phenylthio, phenylsulfoxide,
  • substituted C 5 to C 7 cycloalkenylenes include 4-chloro-l, 3-cyclopentylene and 4-methyl-l, 2-cyclohexylene .
  • heterocycle or “heterocyclic ring” denotes optionally substituted five-membered to eight- membered rings that have 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms.
  • heteroatoms such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms.
  • These five-membered to eight-membered rings may be saturated, fully unsaturated or partially unsaturated, with fully saturated rings being preferred.
  • Preferred heterocyclic rings include morpholino, piperidinyl, piperazinyl, 2-amino-imidazoyl, tetrahydrofurano, pyrrolo, tetrahydrothiophen-yl, hexylmethyleneimino and heptylmethyleneimino.
  • substituted heterocycle or "substituted heterocyclic ring” means the above-described heterocyclic ring is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, C ⁇ to C 12 alkyl, C ⁇ to C 12 alkoxy, C ⁇ to C 12 substituted alkoxy, C : to C 12 acyl, C ⁇ to C 12 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino,
  • heteroaryl means a heterocyclic aromatic derivative which is a five-membered or six- membered ring system having from 1 to 4 heteroatoms, such as oxygen, sulfur and/or nitrogen, in particular nitrogen, either alone or in conjunction with sulfur or oxygen ring atoms.
  • heteroaryls include pyridinyl, pyrimidinyl, and pyrazinyl, pyridazinyl, pyrrolo, furano, oxazolo, isoxazolo, phthalimido, thiazolo and the like.
  • substituted heteroaryl means the above-described heteroaryl is substituted with, for example, one or more, and preferably one or two, substituents which are the same or different which substituents can be halogen, hydroxy, protected hydroxy, cyano, nitro, ⁇ to C 12 alkyl, ⁇ to C 12 alkoxy, C x to C 12 substituted alkoxy, C ⁇ to C 12 acyl, C : to C 12 substituted acyl, C ⁇ to C 12 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, carboxamide, protected carboxamide, N-(C X to C 12 alkyl) carboxamide, protected N- (C x to C 12 alkyl) carboxamide, N, N-di (C ⁇ to
  • C 7 to C 18 phenylalkyl denotes a x to C 12 alkyl group substituted at any position within the alkyl chain by a phenyl.
  • the definition includes groups of the formula: -phenyl-alkyl, -alkyl-phenyl and -alkyl- phenyl-alkyl. Examples of such a group include benzyl, 2-phenylethyl, 3-phenyl (n-propyl) , 4-phenylhexyl, 3- phenyl (n-amyl) , 3-phenyl (sec-butyl) and the like.
  • Preferred C 7 to C 18 phenylalkyl groups are any one of the preferred alkyl groups described herein combined with a phenyl group.
  • C 1 to C 12 heterocycloalkyl denotes a C : to C 12 alkyl group substituted at any position within the alkyl chain by a "heterocycle,” as defined herein.
  • the definition includes groups of the formula: -heterocyclic-alkyl, -alkyl-heterocyclic and -alkyl-heterocyclic-alkyl. Examples of such a group include 2-pyridylethyl, 3-pierydyl (n-propyl) , 4- furylhexyl, 3-piperazyl (n-amyl) , 3-morpholyl (sec-butyl) and the like.
  • C : to C 12 heterocycloalkyl groups are any one of the preferred alkyl groups described herein combined with any one of the preferred heterocycle groups described herein.
  • the terms "C 7 to C 18 substituted phenylalkyl” and "C ⁇ to C 12 substituted heterocycloalkyl” denote a C 7 to C 18 phenylalkyl group or C : to C 12 heterocycloalkyl substituted (on the alkyl or, where applicable, phenyl or heterocyclic portion) with one or more, and preferably one or two, groups chosen from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, guanidino, protected guanidino, heterocyclic ring, substituted heterocyclic ring, C x to C 12 alkyl, C x to C 12 substituted alkyl
  • C 7 to C 18 substituted phenylalkyl include groups such as 2-phenyl-l- chloroethyl, 2- (4-methoxyphenyl) ethyl, 4- (2 , 6-dihydroxy phenyl) n-hexyl, 2- (5-cyano-3-methoxyphenyl) n-pentyl, 3- (2, 6-dimethylphenyl) n-propyl, 4-chloro-3-aminobenzyl, 6- (4-methoxyphenyl) -3-carboxy (n-hexyl) , 5- (4- aminomethylphenyl) - 3- (aminomethyl) n-pentyl, 5-phenyl-3- oxo-n-pent-1-yl and the like.
  • C 7 to C 18 phenylalkylene specifies a C 7 to C 18 phenylalkyl, as defined above, where the phenylalkyl radical is bonded at two different positions connecting together two separate additional groups.
  • the definition includes groups of the formula: -phenyl-alkyl-, -alkyl-phenyl- and -alkyl-phenyl-alkyl- . Substitutions on the phenyl ring can be 1,2, 1,3 or 1,4.
  • C ⁇ to C 18 phenylalkylenes include, for example, 1, 4-toluylene and 1, 3-xylylene .
  • C 1 to C 12 heterocycloalkylene specifies a C ⁇ to C 12 heterocycloalkyl, as defined above, where the heterocycloalkyl radical is bonded at two different positions connecting together two separate additional groups.
  • the definition includes groups of the formula: -heterocyclic-alkyl-, -alkyl-heterocyclic and -alkyl- heterocyclic-alkyl- .
  • C 7 to C 18 substituted phenylalkylene and “C 1 to C 12 substituted heterocycloalkylene” means a C 7 to C 18 phenylalkylene or C ⁇ to C 12 heterocycloalkylene as defined above that is further substituted by halogen, hydroxy, protected hydroxy, C ⁇ to C 10 alkylthio, C x to C 10 alkylsulfoxide, C ⁇ to C 10 alkylsulfonyl, C ⁇ to C 10 substituted alkylthio, C x to C 10 substituted alkylsulfoxide, C x to C 10 substituted alkylsulfonyl, C ⁇ to C 12 alkyl, C- ⁇ to C 12 alkoxy, C ⁇ to C 12 substituted alkyl, C 1 to C 12 alkoxy, oxo, protected oxo, (monosubstituted) amino, (disubstituted) amino, trifluoromethyl, carboxy,
  • substituted phenyl specifies a phenyl group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C x to C 12 alkyl, C : to C 12 substituted alkyl, C ⁇ to C 12 alkoxy, C 1 to C 12 substituted alkoxy, C ⁇ to C 12 acyl, C x to C 12 substituted acyl, C : to C 12 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, carboxamide, protected carboxamide, N-(C X to C 12 alkyl) carboxamide, protected N- (C x to C 12 alkyl) carboxamide, N, N-di ⁇
  • substituted phenyl includes a mono- or di (halo) phenyl group such as 2, 3 or 4-chlorophenyl, 2, 6-dichlorophenyl, 2, 5-dichlorophenyl, 3, 4-dichlorophenyl, 2, 3 or 4-bromophenyl, 3, 4-dibromophenyl, 3-chloro-4-fluorophenyl, 2, 3 or
  • a nitrophenyl group such as 2, 3 or 4-nitrophenyl
  • a cyanophenyl group for example, 2, 3 or 4-cyanophenyl
  • a mono- or di (alkyl) phenyl group such as 2, 3 or 4-methylphenyl, 2, 4-dimethylphenyl, 2, 3 or 4- (iso-propyl) phenyl, 2, 3 or 4-ethylphenyl, 2, 3 or 4- (n-propyl) phenyl and the like
  • a mono or di (alkoxyl) phenyl group for example,
  • substituted phenyl represents disubstituted phenyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxyphenyl, 3-chloro-4- hydroxyphenyl, 2-methoxy-4-bromophenyl, 4-ethyl-2-hydroxyphenyl, 3-hydroxy-4-nitrophenyl, 2-hydroxy 4-chlorophenyl and the like.
  • phenoxy denotes a phenyl bonded to an oxygen atom, wherein the binding to the rest of the molecule is through the oxygen atom.
  • substituted phenoxy specifies a phenoxy group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C x to C 12 alkyl, C x to C 12 alkoxy, C x to C 12 substituted alkoxy, C 1 to C 12 acyl, C x to C 12 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, carboxamide, protected carboxamide, N- (C- L to C 12 alkyl) carboxamide, protected N-(Ci to C 12 al
  • substituted phenoxy examples include
  • 2-bromophenoxy 2-methoxyphenoxy, 2-ethoxyphenoxy, 2-isopropoxyphenoxy, 3-methylphenoxy, 3-ethylphenoxy, 3-isopropylphenoxy, 3-tert-butylphenoxy, 3-pentadecylphenoxy, 3- (trifluoromethyl ) phenoxy, 3-fluorophenoxy, 3-chlorophenoxy, 3-bromophenoxy, 3-iodophenoxy, 3-methoxyphenoxy, 3- (trifluoromethoxy) phenoxy, 4-methylphenoxy, 4-ethylphenoxy, 4-propylphenoxy, 4-isopropylphenoxy, 4-see-butylphenoxy, 4-tert-butylphenoxy, 4-tert-amylphenoxy, 4-nonylphenoxy, 4-dodecylphenoxy, 4-cyclopenylphenoxy, 4- (trifluoromethyl) phenoxy, 4-fluorophenoxy, 4-chlorophenoxy, 4-bromophenoxy, 4-iod
  • C 7 to C 18 substituted phenylalkoxy denotes a C 7 to C 18 phenylalkoxy group bonded to the rest of the molecule through the oxygen atom, wherein the phenylalkyl portion is substituted with one or more, and preferably one or two, groups selected from halogen, hydroxy, protected hydroxy, oxo, protected oxo, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, guanidino, heterocyclic ring, substituted heterocyclic ring, C x to C 12 alkoxy, C ⁇ to C 12 acyl, C x to C 12 acyloxy, nitro, carboxy, protected carboxy, carbamoyl, carboxamide, protected carboxamide, N-(C X to C 12 alkyl) carboxamide, protected N- (C x to C 12 alkyl) carboxamide, N, N
  • C 7 to C 18 substituted phenylalkoxy examples include groups such as 2- (4- hydroxyphenyl) ethoxy, 4- (4-methoxyphenyl) butoxy, (2R)-3- phenyl-2-amino-pro ⁇ oxy, (2S) -3-phenyl-2-amino-propoxy, 2-indanoxy, 6-phenyl-l-hexanoxy, cinnamyloxy,
  • phthalimide means a cyclic imide which is made from phthalic acid, also called
  • substituted phthalimide specifies a phthalimide group substituted with one or more, and preferably one or two, moieties chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C 1 to C 12 alkyl, C x to C 12 alkoxy, C ⁇ to C 12 substituted alkoxy, C ⁇ to C 12 acyl, C x to C 12 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, carboxamide, protected carboxamide, -(Ci to C 12 alkyl) carboxamide, protected N- (C x to C 12 alkyl) carboxamide, N, N-di ⁇ to C 12 alkyl) carboxamide, trifluor
  • substituted phthalimides examples include 4 , 5-dichlorophthalimido, 3-fluorophthalimido, 4-methoxyphthalimido, 3-methylphthalimido, 4-carboxyphthalimido and the like.
  • substituted naphthyl specifies a naphthyl group substituted with one or more, and preferably one or two, moieties either on the same ring or on different rings chosen from the groups consisting of halogen, hydroxy, protected hydroxy, cyano, nitro, C ⁇ to C 6 alkyl, C ⁇ to C 7 alkoxy, C 1 to C 7 acyl, ⁇ to C 7 acyloxy, carboxy, protected carboxy, carboxymethyl, protected carboxymethyl, hydroxymethyl, protected hydroxymethyl, amino, protected amino,
  • substituted naphthyl includes a mono or di (halo) naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-chloronaphthyl, 2, 6-dichloronaphthyl, 2, 5-dichloronaphthyl, 3, 4-dichloronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-bromonaphthyl, 3, 4-dibromonaphthyl, 3-chloro-4-fluoronaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-fluoronaphthyl and the like; a mono or di (hydroxy) naphthyl group such as 1, 2, 3, 4, 5, 6, 7 or 8-hydroxynaphthyl, 2, 4-dihydroxynaphthyl, the protected- hydroxy derivatives thereof and the like; a nitronaphthyl group such as 3- or 4-nitronaphthyl; a cyanon
  • 8-cyanonaphthyl a mono- or di (alkyl) naphthyl group such as 2, 3, 4, 5, 6, 7 or 8-methylnaphthyl, 1, 2, 4-dimethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or 8- (isopropyl) naphthyl, 1, 2, 3, 4, 5, 6, 7 or 8-ethylnaphthyl, 1, 2, 3, 4, 5, 6, 7 or
  • substituted naphthyl represents disubstituted naphthyl groups wherein the substituents are different, for example, 3-methyl-4-hydroxynaphth-l-yl, 3-chloro-4- hydroxynaphth-2-yl, 2-methoxy-4-bromonaphth-l-yl, 4-ethyl-2-hydroxynaphth-l-yl, 3-hydroxy-4-nitronaphth-2- yl, 2-hydroxy-4-chloronaphth-l-yl, 2-methoxy-7- bromonaphth-1-yl, 4-ethyl-5-hydroxynaphth-2-yl, 3-hydroxy-8-nitronaphth-2-yl, 2-hydroxy-5-chloronaphth-l- yl and the like.
  • naphthylene means a naphthyl radical bonded at two positions connecting together two separate additional groups.
  • substituted napthylene means a naphthylene group that is further substituted by halogen, hydroxy, protected hydroxy, C ⁇ to C 10 alkylthio, C x to C 10 alkylsulfoxide, C x to C 10 alkylsulfonyl, C x to C 10 substituted alkylthio, C ⁇ to C 10 substituted alkylsulfoxide, C x to C 10 substituted alkylsulfonyl, C ⁇ to C 12 alkyl, C x to C 12 alkoxy, C ⁇ to C 12 substituted alkyl, C x to C 12 alkoxy, oxo, protected oxo, (monosubstituted) amino, (disubstituted) amino, trifluoromethyl, carboxy, protected carboxy, pheny
  • halo and halogen refer to the fluoro, chloro, bromo or iodo atoms. There can be one or more halogens, which are the same or different. Preferred halogens are chloro and fluoro.
  • (monosubstituted) amino refers to an amino group with one substituent chosen from the group consisting of phenyl, substituted phenyl, C x to C 12 alkyl, C ⁇ to C 12 substituted alkyl, C x to C 12 acyl, C ⁇ to C 12 substituted acyl, C 2 to C 12 alkenyl, C 2 to C 12 substituted alkenyl, C 2 to C 12 alkynyl, C 2 to C 12 substituted alkynyl, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, heterocyclic ring, substituted heterocyclic ring, C ⁇ to C 12 heterocycloalkyl and C x to C 12 substituted heterocycloalkyl.
  • the (monosubstituted) amino can additionally have an amino-protecting group as encompassed by the term "protected (monosubstituted) amino.
  • (disubstituted) amino refers to an amino group with two substituents chosen from the group consisting of phenyl, substituted phenyl, C x to C 12 alkyl, C ⁇ to C 12 substituted alkyl, C ⁇ to C 12 acyl, C 2 to C 12 alkenyl, C 2 to C 12 alkynyl, C 7 to C 18 phenylalkyl, C 7 to C 18 substituted phenylalkyl, C-. to C 12 heterocycloalkyl and C : to C 12 substituted heterocycloalkyl, .
  • the two substituents can be the same or different.
  • amino-protecting group refers to substituents of the amino group commonly employed to block or protect the amino functionality while reacting other functional groups of the molecule.
  • protected (monosubstituted) amino means there is an amino-protecting group on the monosubstituted amino nitrogen atom.
  • protected carboxamide means there is an amino-protecting group on the carboxamide nitrogen.
  • protected N-(C X to C 12 alkyl) carboxamide means there is an amino- protecting group on the carboxamide nitrogen.
  • amino-protecting groups include the formyl ("For") group, the trityl group, the phthalimido group, the trichloroacetyl group, the chloroacetyl, bromoacetyl, and iodoacetyl groups, urethane-type blocking groups, such as t-butoxycarbonyl ("Boc”), 2- (4-biphenylyl) propyl-2-oxycarbonyl ("Bpoc”), 2-phenylpropyl-2-oxycarbonyl (“Poc”) , 2- (4-xenyl) isopropoxycarbonyl, 1, 1-diphenylethyl-l- oxycarbonyl, 1, 1-diphenylpropyl-l-oxycarbonyl, 2- (3, 5- dimethoxyphenyl) propyl-2-oxycarbonyl ("Ddz”), 2- (p- toluyl) propyl-2-oxycarbonyl, cyclopentanyloxycarbonyl, 1-methoxycarbon
  • amino-protecting group employed is not critical so long as the derivatized amino group is stable to the conditions of the subsequent reaction (s) and can be removed at the appropriate point without disrupting the remainder of the compounds.
  • Preferred amino-protecting groups are Boc, Cbz and Fmoc.
  • Further examples of amino-protecting groups embraced by the above term are well known in organic synthesis and the peptide art and are described by, for example, T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapter 7, M. Bodanzsky,
  • carboxy-protecting group refers to one of the ester derivatives of the carboxylic acid group commonly employed to block or protect the carboxylic acid group while reactions are carried out on other functional groups on the compound.
  • carboxylic acid protecting groups include t-butyl, 4-nitrobenzyl, 4-methoxybenzyl, 3, 4-dimethoxybenzyl, 2, 4-dimethoxybenzyl, 2, 4, 6-trimethoxybenzyl, 2, 4, 6-trimethylbenzyl, pentamethylbenzyl, 3, 4-methylenedioxybenzyl, benzhydryl, 4,4' -dimethoxytrityl, 4,4', "-trimethoxytrityl, 2-phenylpropyl, trimethylsilyl, t-butyldimethylsilyl, phenacyl, 2, 2, 2-trichloroethyl, - (trimethylsilyl) ethyl, - (di (n-butyl) methyls
  • carboxy-protecting group employed is not critical so long as the derivatized carboxylic acid is stable to the conditions of subsequent reaction (s) and can be removed at the appropriate point without disrupting the remainder of the molecule. Further examples of these groups are found in E. Haslam, "Protective Groups in Organic Chemistry,” J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapter 5, and T.W. Greene and P.G.M. Wuts, "Protective Groups in
  • hydroxy-protecting group refers to readily cleavable groups bonded to hydroxyl groups, such as the tetrahydropyranyl, 2-methoxypropyl, 1-ethoxyethyl, methoxymethyl, 2-methoxyethoxymethyl, methylthiomethyl, t-butyl, t-amyl, trityl, 4-methoxytrityl, 4, 4 ' -dimethoxytrityl, , ' , 4 "-trimethoxytrityl, benzyl, allyl, trimethylsilyl, (t-butyl) dimethylsilyl, 2, 2, 2-trichloroethoxycarbonyl groups and the like.
  • hydroxy-protecting groups are not critical so long as the derivatized hydroxyl group is stable to the conditions of subsequent reaction (s) and can be removed at the appropriate point without disrupting the remainder of the molecule.
  • Further examples of hydroxy-protecting groups are described by C.B. Reese and E. Haslam, "Protective Groups in Organic Chemistry,” J.G.W. McOmie, Ed., Plenum Press, New York, NY, 1973, Chapters 3 and 4, respectively, and T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," 2nd ed., John Wiley and Sons, New York, NY, 1991, Chapters 2 and 3.
  • Related terms are "protected hydroxy, " and “protected hydroxymethyl” which refer to a hydroxy or hydroxymethyl substituted with one of the above hydroxy-protecting groups.
  • C ⁇ to C 10 alkylthio refers to sulfide groups such as methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, t-butylthio and like groups.
  • C 1 to C 10 alkylsulfoxide indicates sulfoxide groups such as methylsulfoxide, ethylsulfoxide, n- propylsulfoxide, isopropylsulfoxide, n-butylsulfoxide, sec-butylsulfoxide and the like.
  • C ⁇ to C 10 alkylsulfonyl encompasses groups such as methylsulfonyl, ethylsulfonyl, n-propylsulfonyl, isopropylsulfonyl, n- butylsulfonyl, t-butylsulfonyl and the like. It should also be understood that the above thio, sulfoxide or sulfonyl groups can be at any point on the alkyl chain (e.g., 2-methylmercaptoethyl) .
  • Ci to C 10 substituted alkylthio Ci to C 10 substituted alkylsulfoxide
  • C ⁇ to C 10 substituted alkylsulfonyl denote the C x to C 10 alkyl portion of these groups may be substituted as described above in relation to "substituted alkyl.”
  • phenylthio " "phenylsulfoxide, “ and “phenylsulfonyl” specify a thiol, a sulfoxide, or sulfone, respectively, containing a phenyl group.
  • substituted phenylthio " “substituted phenylsulfoxide, " and “substituted phenylsulfonyl” means that the phenyl of these groups can be substituted as described above in relation to "substituted phenyl.”
  • C ⁇ to C 12 alkylaminocarbonyl means a C ⁇ to C 12 alkyl attached to a nitrogen of the aminocarbonyl group.
  • Examples of C ⁇ to C 12 alkylaminocarbonyl include methylaminocarbonyl, ethylaminocarbonyl, propylaminocarbonyl and butylaminocarbonyl .
  • the term "Ci to C 12 substituted alkylaminocarbonyl” denotes a substituted alkyl bonded to a nitrogen of the aminocarbonyl group, which alkyl may be substituted as described above in relation to C x to C 12 substituted alkyl.
  • C x to C 12 substituted alkylaminocarbonyl examples include, for example, methoxymethylaminocarbonyl, 2-chloroethylaminocarbonyl, 2-oxopropylaminocarbonyl and 4-phenylbutylaminocarbonyl .
  • C to C 12 alkoxycarbonyl means a "Cj to C 12 alkoxy” group attached to a carbonyl group.
  • C ⁇ to C 12 substituted alkoxycarbonyl denotes a substituted alkoxy bonded to the carbonyl group, which alkoxy may be substituted as described above in relation to w Cj . to C 12 substituted alkyl.”
  • phenylaminocarbonyl means a phenyl attached to a nitrogen of the aminocarbonyl group.
  • substituted phenylaminocarbonyl denotes a substituted phenyl bonded to a nitrogen of the aminocarbonyl group, which phenyl may be substituted as described above in relation to substituted phenyl.
  • substituted phenylaminocarbonyl include 2-chlorophenylaminocarbonyl, 3-chlorophenylaminocarbonyl , 2-nitorphenylaminocarbonyl, 4-biphenylaminocarbonyl, and 4-methoxyphenylaminocarbonyl .
  • C 1 to C 12 alkylaminothiocarbonyl means a C ⁇ to C 12 alkyl attached to an aminothiocarbonyl group, wherein the alkyl has the same meaning as defined above.
  • Examples of C ⁇ to C 12 alkylaminothiocarbonyl include methylaminothiocarbonyl, ethylaminothiocarbonyl, propylaminothiocarbonyl and butylaminothiocarbonyl .
  • C 1 to C 12 substituted alkylaminothiocarbonyl denotes a substituted alkyl bonded to an aminothiocarbonyl group, wherein the alkyl may be substituted as described above in relation to C x to C 12 substituted alkyl.
  • Examples of C ⁇ to C 12 substituted alkylaminothiocarbonyl include, for example, methoxymethylaminothiocarbonyl, 2-chloroethylaminothiocarbonyl, 2-oxopropylaminothiocarbonyl and 4-phenylbutylaminothiocarbonyl .
  • phenylaminothiocarbonyl means a phenyl attached to an aminothiocarbonyl group, wherein the phenyl has the same meaning as defined above.
  • substituted phenylaminothiocarbonyl denotes a substituted phenyl bonded to an aminothiocarbonyl group, wherein phenyl may be substituted as described above in relation to substituted phenyl.
  • substituted phenylaminothiocarbonyls include 2-chlorophenylaminothiocarbonyl,
  • phenylene means a phenyl group where the phenyl radical is bonded at two positions connecting together two separate additional groups. Examples of “phenylene” include 1, 2-phenylene, 1, 3-phenylene, and 1, 4-phenylene.
  • substituted phenylene means a phenyl group where the phenyl radical is bonded at two positions connecting together two separate additional groups, wherein the phenyl is substituted as described above in relation to "substituted phenyl.”
  • substituted C ⁇ to C 12 alkylene means a C ⁇ to C 12 alkyl group where the alkyl radical is bonded at two positions connecting together two separate additional groups and further bearing an additional substituent.
  • substituted C x to C 12 alkylene includes aminomethylene, 1- (amino) -1, 2-ethyl, 2- (amino) - 1,2-ethyl, 1- (acetamido) -1, 2-ethyl, 2- (acetamido) -1, 2- ethyl, 2-hydroxy-l, 1-ethyl, 1- (amino) -1, 3-propyl .
  • substituted cyclic C 2 to C 7 alkylene "cyclic C 2 to C 7 heteroalkylene, " and “substituted cyclic C 2 to C 7 heteroalkylene, " defines such a cyclic group bonded (“fused") to the phenyl radical resulting in a bicyclic ring system.
  • the cyclic group may be saturated or contain one or two double bonds.
  • the cyclic group may have one or two methylene or methine groups replaced by one or two oxygen, nitrogen or sulfur atoms which are the cyclic C 2 to C 7 heteroalkylene.
  • the cyclic alkylene or heteroalkylene group may be substituted once or twice by the same or different substituents which, if appropriate, can be connected to another part of the compound (e.g., alkylene) selected from the group consisting of the following moieties: hydroxy, protected hydroxy, carboxy, protected carboxy, oxo, protected oxo, C x to C 4 acyloxy, formyl, ⁇ to C 12 acyl, C x to C 12 alkyl, C x to C 7 alkoxy, C x to C 10 alkylthio, C : to C 10 alkylsulfoxide, C : to C 10 alkylsulfonyl, halo, amino, protected amino, (monosubstituted) amino, protected (monosubstituted) amino, (disubstituted) amino, hydroxymethyl or a protected hydroxymethyl.
  • substituents e.g., alkylene
  • the cyclic alkylene or heteroalkylene group fused onto the benzene radical can contain two to ten ring members, but it preferably contains three to six members.
  • saturated cyclic groups are when the resultant bicyclic ring system is 2,3-dihydro- indanyl and a tetralin ring.
  • unsaturated examples occur when the resultant bicyclic ring system is a naphthyl ring or indolyl.
  • fused cyclic groups which each contain one nitrogen atom and one or more double bond, preferably one or two double bonds, are when the benzene radical is fused to a pyridino, pyrano, pyrrolo, pyridinyl, dihydropyrrolo, or dihydropyridinyl ring.
  • fused cyclic groups which each contain one oxygen atom and one or two double bonds are when the benzene radical ring is fused to a furo, pyrano, dihydrofurano, or dihydropyrano ring.
  • fused cyclic groups which each have one sulfur atom and contain one or two double bonds are when the benzene radical is fused to a thieno, thiopyrano, dihydrothieno or dihydrothiopyrano ring.
  • cyclic groups which contain two heteroatoms selected from sulfur and nitrogen and one or two double bonds are when the benzene radical ring is fused to a thiazolo, isothiazolo, dihydrothiazolo or dihydroisothiazolo ring.
  • Examples of cyclic groups which contain two heteroatoms selected from oxygen and nitrogen and one or two double bonds are when the benzene ring is fused to an oxazolo, isoxazolo, dihydrooxazolo or dihydroisoxazolo ring.
  • Examples of cyclic groups which contain two nitrogen heteroatoms and one or two double bonds occur when the benzene ring is fused to a pyrazolo, imidazolo, dihydropyrazolo or dihydroimidazolo ring or pyrazinyl.
  • carbamoyl means an -NCO- group where the radical is bonded at two positions connecting two separate additional groups.
  • salt encompasses those salts that form with the carboxylate anions and amine nitrogens and include salts formed with the organic and inorganic anions and cations discussed below. Furthermore, the term includes salts that form by standard acid-base reactions with basic groups (such as amino groups) and organic or inorganic acids.
  • Such acids include hydrochloric, hydrofluoric, trifluoroacetic, sulfuric, phosphoric, acetic, succinic, citric, lactic, maleic, fumaric, palmitic, cholic, pamoic, mucic, D-glutamic, D-camphoric, glutaric, phthalic, tartaric, lauric, stearic, salicyclic, methanesulfonic, benzenesulfonic, sorbic, picric, benzoic, cinnamic, and like acids.
  • organic or inorganic cation refers to counter-ions for the carboxylate anion of a carboxylate salt.
  • the counter-ions are chosen from the alkali and alkaline earth metals, (such as lithium, sodium, potassium, barium, aluminum and calcium) ; ammonium and mono-, di- and tri-alkyl amines such as trimethylamine, cyclohexylamine; and the organic cations, such as dibenzylammonium, benzylammonium, 2-hydroxyethylammonium, bis (2-hydroxyethyl) ammonium, phenylethylbenzylammonium, dibenzylethylenediammonium, and like cations.
  • the compounds of the invention can also exist as solvates and hydrates. Thus, these compounds may crystallize with, for example, waters of hydration, or one, a number of, or any fraction thereof of molecules of the mother liquor solvent.
  • the solvates and hydrates of such compounds are included within the scope of this invention.
  • One or more compounds of the invention can be in the biologically active ester form, such as the non-toxic, metabolically-labile ester-form.
  • ester forms induce increased blood levels and prolong the efficacy of the corresponding non- esterified forms of the compounds.
  • Ester groups which can be used include the lower alkoxymethyl groups, for example, methoxymethyl, ethoxymethyl, isopropoxymethyl and the like; the - (C 1 to C 12 ) alkoxyethyl groups, for example methoxyethyl, ethoxyethyl, propoxyethyl, isopropoxyethyl and the like; the 2-oxo-l, 3-diooxlen-4- ylmethyl groups, such as 5-methyl-2-oxo-l, 3-dioxolen-4- ylmethyl, 5-phenyl-2-oxo-l, 3-dioxolen-4-ylmethyl and the like; the C ⁇ to C 10 alkylthiomethyl groups, for example methylthiomethyl, ethylthiomethyl, iso-propylthiomethyl and the like; the acyloxymethyl groups, for example pivaloyloxymethyl, pivaloyloxyethyl, -ace
  • amino acid includes any one of the twenty naturally-occurring amino acids or the D-form of any one of the naturally-occurring amino acids.
  • amino acid also includes other non-naturally occurring amino acids besides the D-amino acids, which are functional equivalents of the naturally- occurring amino acids.
  • non-naturally-occurring amino acids include, for example, norleucine ("Nle”), norvaline (“Nva”), L- or D- naphthalanine, ornithine (“Orn”), homoarginine (homoArg) and others well known in the peptide art, such as those described in M.
  • the term "functionalized resin” means any resin, crosslinked or otherwise, where functional groups have been introduced into the resin, as is common in the art. Such resins include, for example, those functionalized with amino, alkylhalo, formyl or hydroxy groups. Such resins which can serve as solid supports are well known in the art and include, for example, 4-methylbenzhydrylamine-copoly (styrene-1% divinylbenzene) (MBHA), 4-hydroxymethylphenoxymethyl-copoly (styrene-1% divinylbenzene) , 4-oxymethyl-phenyl-acetamido- copoly (stryene-1% divinylbenzene) (Wang) , 4- (oxymethyl) - phenylacetamido methyl (Pam), and TentagelTM, from Rapp Polymere Gmbh, trialkoxy-diphenyl-methyl ester- copoly (styrene-1% divinylbenzene) (RINK) all of which are commercial
  • a "combinatorial library” is an intentionally created collection of differing molecules which can be prepared by the means provided below or otherwise and screened for biological activity in a variety of formats (e.g., libraries of soluble molecules, libraries of compounds attached to resin beads, silica chips or other solid supports).
  • a "combinatorial library, " as defined above, involves successive rounds of chemical syntheses based on a common starting structure.
  • the combinatorial libraries can be screened in any variety of assays, such as those detailed below as well as others useful for assessing their biological activity.
  • the combinatorial libraries will generally have at least one active compound and are generally prepared such that the compounds are in equimolar quantities.
  • a combinatorial library of the invention can contain two or more of the above-described compounds.
  • the invention further provides a combinatorial library containing three, four or five or more of the above-described compounds.
  • a combinatorial library can contain ten or more of the above-described compounds.
  • a combinatorial library can contain fifty or more of the above-described compounds. If desired, a combinatorial library of the invention can contain 100,000 or more, or even 1,000,000 or more, of the above-described compounds.
  • the preparation of the combinatorial libraries can use the "split resin approach.”
  • the split resin approach is described by, for example, U.S. Patent 5,010,175 to Rutter, WO PCT 91/19735 to Simon, and Gallop et al., J. Med. Chem . , 37:1233-1251 (1994), all of which are incorporated herein by reference .
  • amino acids are indicated herein by either their full name or by the commonly known three letter code. Further, in the naming of amino acids, "D-" designates an amino acid having the "D" configuration, as opposed to the naturally occurring L-amino acids. Where no specific configuration is indicated, one skilled in the art would understand the amino acid to be an L-amino acid.
  • the amino acids can, however, also be in racemic mixtures of the D- and L-configuration or the D-amino acid can readily be substituted for that in the L-configuration .
  • inert, pharmaceutically acceptable carriers are used.
  • the pharmaceutical carrier can be either solid or liquid. Solid form preparations include, for example, powders, tablets, dispersible granules, capsules, cachets, and suppositories .
  • a solid carrier can be one or more substances which can also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or tablet disintegrating agents; it can also be an encapsulating material.
  • the carrier is generally a finely divided solid which is in a mixture with the finely divided active component.
  • the active compound is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
  • a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient-sized molds and allowed to cool and solidify.
  • Powders and tablets preferably contain between about 5% to about 70% by weight of the active ingredient.
  • Suitable carriers include, for example, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, a low-melting wax, cocoa butter and the like.
  • compositions can include the formulation of the active compound with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier, which is thus in association with it.
  • a carrier which is thus in association with it.
  • cachets are also included. Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
  • Liquid pharmaceutical compositions include, for example, solutions suitable for oral or parenteral administration, or suspensions, and emulsions suitable for oral administration.
  • Sterile water solutions of the active component or sterile solutions of the active component in solvents comprising water, ethanol, or propylene glycol are examples of liquid compositions suitable for parenteral administration.
  • Sterile solutions can be prepared by dissolving the active component in the desired solvent system, and then passing the resulting solution through a membrane filter to sterilize it or, alternatively, by dissolving the sterile compound in a previously sterilized solvent under sterile conditions.
  • Aqueous solutions for oral administration can be prepared by dissolving the active compound in water and adding suitable flavorants, coloring agents, stabilizers, and thickening agents as desired.
  • Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
  • the pharmaceutical composition is in unit dosage form.
  • the composition is divided into unit doses containing appropriate quantities of the active benzimidazole compound.
  • the unit dosage form can be a packaged preparation, the package containing discrete quantities of the preparation, for example, packeted tablets, capsules, and powders in vials or ampules.
  • the unit dosage form can also be a capsule, cachet, or tablet itself, or it can be the appropriate number of any of these packaged forms.
  • the compounds of the present invention are generally in a pharmaceutical composition so as to be administered to a subject at dosage levels of from 0.7 to 7000 mg per day, and preferably 1 to 500 mg per day, for a normal human adult of approximately 70 kg of body weight, this translates into a dosage of from 0.01 to 100 mg/kg of body weight per day.
  • the specific dosages employed can be varied depending upon the requirements of the patient, the severity of the condition being treated, and the activity of the compound being employed. The determination of optimum dosages for a particular situation is within the skill of the art.
  • the compounds and combinatorial libraries of the invention can be prepared as set forth in Figure 1 and as described below.
  • Variant benzimidazole derivative compounds and combinatorial libraries can be prepared in order to achieve a high level of diversity. For instance, an N-protected amino acid can be coupled to an amine compound and then deprotected, resulting in a carboxamido substituted amino compound having a substituent of the formula -NH-C (0) -variable group-NH 2 .
  • a diamine containing a variable group can be coupled to an amine compound in the presence of carbonyldiimidazole (CDI), resulting in an ureido substituted amino compound having a substituent of the formula -NH-C (0) -NH-variable group-NH 2 .
  • CDI carbonyldiimidazole
  • the amine compound can be attached to solid support, such as a functionalized resin (e.g., methylbenzhydrylamine (MBHA) .
  • a functionalized resin e.g., methylbenzhydrylamine (MBHA) .
  • MBHA methylbenzhydrylamine
  • Merrifield resin can be coupled with a primary amine, resulting in the resin attached to a substituent of the formula -HN-variable group. Subsequently, the substituent can be coupled with an amino acid resulting in a group of the formula -HN-variable group-C(O)- variable group.
  • the carboxamido substituted amino compound can then be coupled to a phenyl compound with a nitro and a halo group at ortho positions, resulting in a phenyl compound substituted with a nitro group and an ortho-monosubstituted amino group.
  • the phenyl compound being coupled can also have one to four additional substituents, such as carboxyl, halo, alkyl, etc. (see Figure 1) .
  • this substituent can be reacted with a (i) monosubstituted amine; (ii) disubstituted amine; (iii) cyclic imide; or (iv) alcohol; resulting, respectively, in a (i) monosubstituted carboxamido substituent; (ii) disubstituted carboxamido substituent; (iii) cyclic imido carbonyl substituent; or (iv) ester substituent attached to the phenyl compound (see Figure 1) . It should be understood that such a substituent can be at any one to four of the available positions on the phenyl ring.
  • the nitro group of the phenyl compound can be reduced.
  • the resulting compound can be coupled with an aldehyde compound and cleaved(see Figure 1).
  • the amino group can be substituted.
  • the amino group can be alkylated with an alkyl halide or substituted alkyl halide .
  • Resin-bound benzimidazole derivative compounds can be cleaved by treating them, for example, with HF gas.
  • the compounds can be extracted from the spent resin, for example, with AcOH (see Figure 1) .
  • Benzimidazole derivative compounds and libraries can be made utilizing individual polyethylene bags, referred to as "tea bags" (see Houghten et al., Proc . Na tl . Acad.
  • the nonsupport-bound combinatorial libraries can be screened as single compounds.
  • the nonsupport-bound combinatorial libraries can be screened as mixtures in solution in assays such as radio-receptor inhibition assays, anti-bacterial assays, anti-fungal assays, calmodulin-dependent phosphodiesterase (CaMPDE) assays and phosphodiesterase (PDE) assays, as described in detail below.
  • Deconvolution of highly active mixtures can then be carried out by iterative or positional scanning methods. These techniques, the iterative approach or the positional scanning approach, can be utilized for finding other active compounds within the combinatorial libraries of the present invention using any one of the below-described assays or others well known in the art.
  • a new sub-library with the first two variable positions defined is reacted again with all the other possibilities at the remaining undefined variable position.
  • the identity of the third variable position in the sub-library having the highest activity is determined. If more variables exist, this process is repeated for all variables, yielding the compound with each variable contributing to the highest desired activity in the screening process. Promising compounds from this process can then be synthesized on larger scale in traditional single-compound synthetic methods for further biological investigation.
  • the optimum substituent at that position can be determined, pointing to the optimum or at least a series of compounds having a maximum of the desired biological activity.
  • the number of sublibraries for compounds with a single position defined will be the number of different substituents desired at that position, and the number of all the compounds in each sublibrary will be the product of the number of substituents at each of the other variables .
  • the compounds of the present invention can be used for a variety of purposes and indications and as medicaments for any such purposes and indications.
  • benzimidazole derivative compounds of the present invention can be used as pesticides, acaricides, receptor agonists or antagonists and antimicrobial agents, including antibacterial or antiviral agents.
  • the libraries can be screened in any variety of melanocortin receptor and related activity assays, such as those detailed below as well as others known in the art.
  • the subject compounds can be useful as analgesics.
  • Assays which can be used to test the biological activity of the instant compounds include antimicrobial assays, a competitive enzyme-linked immunoabsorbent assay and radio-receptor assays, as described below.
  • the melanocortin (MC) receptors are a group of cell surface proteins that mediate a variety of physiological effects, including regulation of adrenal gland function such as production of the glucocorticoids cortisol and aldosterone; control of melanocyte growth and pigment production; thermoregulation; immunomodulation; and analgesia.
  • Five distinct MC receptors have been cloned and are expressed in a variety of tissues, including melanocytes, adrenal cortex, brain, gut, placenta, skeletal muscle, lung, spleen, thymus, bone marrow, pituitary, gonads and adipose tissue (Tatro, Neuroimmunomodulation 3:259-284 (1996)).
  • Three MC receptors, MCR-1, MCR-3 and MCR-4 are expressed in brain tissue (Xia et al . , Neuroreport 6:2193-2196 (1995) ) .
  • melanocortins function as agonists that stimulate the activity of MC receptors.
  • the melanocortins include melanocyte-stimulating hormones (MSH) such as ⁇ -MSH, ⁇ -MSH and ⁇ -MSH, as well as adrenocorticotropic hormone (ACTH) .
  • MSH melanocyte-stimulating hormones
  • ACTH adrenocorticotropic hormone
  • Individual ligands can bind to multiple MC receptors with differing relative affinities.
  • the variety of ligands and MC receptors with differential tissue-specific expression likely provides the molecular basis for the diverse physiological effects of melanocortins and MC receptors.
  • ⁇ -MSH antagonizes the actions of immunological substances such as cytokines and acts to modulate fever, inflammation and immune responses (Catania and Lipton, Annals N. Y. Acad. Sci. 680:412-423 (1993)).
  • MCR-1 is involved in pain and inflammation.
  • MCR-1 mRNA is expressed in neutrophils (Catania et al., Peptides 17:675-679 (1996)).
  • the anti-inflammatory agent ⁇ -MSH was found to inhibit migration of neutrophils.
  • the presence of MCR-1 in neutrophils correlates with the anti-inflammatory activity of ⁇ -MSH.
  • MC receptors Due to the varied physiological activities of MC receptors, high affinity ligands of MC receptors could be used to exploit the varied physiological responses of MC receptors by functioning as potential therapeutic agents or as lead compounds for the development of therapeutic agents. Furthermore, due to the effect of MC receptors on the activity of various cytokines, high affinity MC receptor ligands could also be used to regulate cytokine activity.
  • a variety of assays can be used to identify or characterize MC receptor ligands of the invention.
  • the ability of a benzimidazole derivative compound to compete for binding of a known MC receptor ligand can be used to assess the affinity and specificity of a benzimidazole compound for one or more MC receptors.
  • Any MC receptor ligand can be used so long as the ligand can be labeled with a detectable moiety.
  • the detectable moiety can be, for example, a radiolabel, fluorescent label or chromophore, or any detectable functional moiety so long as the MC receptor ligand exhibits specific MC receptor binding.
  • a particularly useful detectable MC receptor ligand for identifying and characterizing other MC receptor ligands is 125 I-HP 467, which has the amino acid sequence Ac-Nle-Gln-His- (p(I) -D- Phe) -Arg- (D-Trp) -Gly-NH 2 and is described in Dooley et al., "Melanocortin Receptor Ligands and Methods of Using Same," U.S. patent application 09/027,108, filed February 20, 1998, which is incorporated herein by reference.
  • HP 467 is a para-iodinated form of HP 228.
  • benzimidazole compounds of the invention bind to one or more MC receptors.
  • benzimidazole derivative compounds of the invention can exhibit a range of affinities and specificity for various MC receptors.
  • the invention provides MC receptor ligands that can bind to several MC receptors with similar affinity.
  • the invention also provides MC receptor ligands that can be selective for one or more MC receptors.
  • selective means that the affinity of a MC receptor ligand differs between one MC receptor and another by about 10-fold, generally about 20- to 50-fold, and particularly about 100-fold.
  • a MC receptor ligand having broad specificity is desired.
  • MCR-1 ligands are particularly useful for treating pain and inflammation, whereas MCR-4 ligands are useful for treating obesity.
  • the binding characteristics and specificity of a given MC receptor ligand can be selected based on the particular disease or physiological effect that is desired to be altered.
  • MC receptors are G protein-coupled receptors that couple to adenylate cyclase and produce cAMP. Therefore, measuring cAMP production in a cell expressing a MC receptor and treated with a MC receptor ligand can be used to assess the function of the MC receptor ligand in activating a MC receptor.
  • Ligands for MC-3 that can alter the activity of an MC-3 receptor can be useful for treating sexual dysfunction and other conditions or conditions associated with MC-3 such as inflammation.
  • Other MC-3-associated conditions that can be treated with the MC-3 receptor ligands include disuse deconditioning; organ damage such as organ transplantation or ischemic injury; adverse reactions associated with cancer chemotherapy; diseases such as atherosclerosis that are mediated by free radicals and nitric oxide action; bacterial endotoxic sepsis and related shock; adult respiratory distress syndrome; and autoimmune or other patho-immunogenic diseases or reactions such as allergic reactions or anaphylaxis, rheumatoid arthritis, inflammatory bowel disease, ulcerative colitis, glomerulonephritis, systemic lupus erythematosus, transplant atherosclerosis and parasitic mediated immune dysfunctions such as Chagas's Disease.
  • the invention further provides a method for treating an MC-3-associated condition in a subject.
  • MC-3-associated condition includes any condition or condition mediated by MC-3 or can be affected by binding an MC-3 ligand. Such conditions include inflammation and sexual dysfunction.
  • sexual dysfunction means any condition that inhibits or impairs normal sexual function, including coitus. However, the term need not be limited to physiological conditions, but may include psychogenic conditions or perceived impairment without a formal diagnosis of pathology.
  • sexual dysfunction In males, sexual dysfunction includes erectile dysfunction.
  • erectile dysfunction or “impotence” means herein the inability or impaired ability to attain or sustain an erection that would be of satisfactory rigidity for coitus.
  • sexual dysfunction in males can also include premature ejaculation and priapism, which is a condition of prolonged and sometimes painful erection unrelated to sexual activity, often associated with sickle-cell disease.
  • sexual dysfunction includes sexual arousal disorder.
  • the term "sexual arousal disorder” means herein a persistent or recurrent failure to attain or maintain the lubrication-swelling response of sexual excitement until completion of sexual activity.
  • sexual dysfunction in females can also include inhibited orgasm and dyspareunia, which is painful or difficult coitus. Sexual dysfunction can also be manifested as inhibited sexual desire or inhibited lordosis behavior in animals.
  • the ability of the compounds to inhibit bacterial growth, and therefore be useful to that infection can be determined by methods well known in the art.
  • Compounds of the present invention were shown to have antimicrobial activity by the in vi tro antimicrobial activity assay described below and, therefore, are useful as antimicrobial agents (see Example 16) .
  • the concentration of cells is established by plating 100 ⁇ l of the culture solution using serial dilutions (e.g., 10 "2 , 10 ⁇ 3 and 10 "4 ) onto solid agar plates.
  • serial dilutions e.g., 10 "2 , 10 ⁇ 3 and 10 "4
  • compounds, individual or in mixtures are added to the bacterial suspension at concentrations derived from serial two-fold dilutions ranging from 1500 to 2.9 ⁇ g/ml.
  • the plates are incubated overnight at 37°C and the growth determined at each concentration by OD 620 nm.
  • the IC 50 (the concentration necessary to inhibit 50% of the growth of the bacteria) can then be calculated.
  • the competitive ELISA method which can be used here is a modification of the direct ELISA technique described previously in Appel et al . , J. Immunol.
  • multi-well microplates are coated with the antigenic peptide (Ac-GASPYPNLSNQQT-NH 2 ) at a concentration of 100 pmol/50 ⁇ l .
  • MAb 125-10F3 Appel et al., supra ) (25 ⁇ l per well) .
  • the MAb is added at a fixed dilution in which the bicyclic guanidine in solution effectively competes for MAb binding with the antigenic peptide adsorbed to the plate.
  • the remaining steps are the same as for direct ELISA.
  • the concentration of compound necessary to inhibit 50% of the MAb binding to the control peptide on the plate (IC 50 ) is determined by serial dilutions of the compound.
  • radio- receptor assays can be selective for any one of the ⁇ , K, or ⁇ opiate receptors.
  • Compounds of the present invention can be useful in vitro for the diagnosis of relevant opioid receptor subtypes, such as K, in the brain and other tissue samples. Similarly, the compounds can be used in vivo diagnostically to localize opioid receptor subtypes.
  • the radio-receptor assays are also an indication of the compounds' analgesic properties as described, for example, in Dooley et al., Proc . Na tl . Acad. Sci . , 90:10811-10815 (1993).
  • these compounds can be used for therapeutic purposes to block the peripheral effects of a centrally acting pain killer.
  • morphine is a centrally acting pain killer.
  • Morphine has a number of deleterious effects in the periphery which are not required for the desired analgesic effects, such as constipation and pruritus (itching).
  • the subject compounds can have value in blocking the periphery effects of morphine, such as constipation and pruritus. Accordingly, the subject compounds can also be useful as drugs, namely as analgesics, or to treat pathologies associated with other compounds which interact with the opioid receptor system. Additionally, such compounds can be tested in a ⁇ receptor assay. Ligands for the ⁇ receptor can be useful as antipsychotic agents, as described in Abou- Gharbia et al., Annual Reports in Medicinal Chemistry, 28:1-10 (1993).
  • Radio-receptor assays can be performed with particulate membranes prepared using a modification of the method described in Pasternak et al., Mol . Pharmacol . 11:340-351 (1975), which is incorporated herein by reference.
  • Rat brains frozen in liquid nitrogen can be obtained from Rockland (Gilbertsville, PA) . The brains are thawed, the cerebella removed and the remaining tissue weighed. Each brain is individually homogenized in 40 ml Tris-HCl buffer (50 mM, pH 7.4, 4°C) and centrifuged (Sorvall ® RC5C SA-600: Du Pont, Wilmington, DE) (16,000 rpm) for 10 minutes.
  • the pellets are resuspended in fresh Tris-HCl buffer and incubated at 37°C for 40 minutes. Following incubation, the suspensions are centrifuged as before, the resulting pellets resuspended in 100 volumes of Tris buffer and the suspensions combined. Membrane suspensions are prepared and used in the same day. Protein content of the crude homogenates generally range from 0.15-0.2 mg/ml as determined using the method described in Bradford, M.M., Anal . Biochem . 72:248-254 (1976), which is incorporated herein by reference.
  • reaction is terminated by filtration through GF-B filters on a Tomtec harvester (Orange, CT) .
  • the filters are subsequently washed with 6 ml of Tris-HCl buffer, 4°C.
  • Bound radioactivity is counted on a Pharmacia Biotech Betaplate Liquid Scintillation Counter (Piscataway, NJ) and expressed in cpm.
  • standard curves in which 3 H-DAMGO is incubated in the presence of a range of concentrations of unlabeled DAMGO (0.13-3900 nM) are generally included in each plate of each assay (a 96-well format) .
  • IC 50 values (the concentration necessary to inhibit 50% of 3 H-DAMGO binding) are then calculated. IC 50 values of less than 1000 nM are indicative of highly active opioid compounds which bind to the ⁇ receptor, with particularly active compounds having IC 50 values of 100 nM or less and the most active compounds with values of less than 10 nM.
  • assays selective for K receptors can be carried out using [ 3 H]-U69,593 (3 nM, specific activity 62 Ci/mmol) as radioligand.
  • Assays selective for ⁇ opiate receptors can be carried out using tritiated DSLET ( [D- Ser 2 , D-Leu 5 ] -threonine-enkephalin) as radioligand.
  • Assays selective for the ⁇ opiate receptor can use radiolabeled pentazocine as ligand. Screening of combinatorial libraries and compounds of the invention can be done with an anti-fungal assay. Compounds of the present invention can be useful for treating fungal infections.
  • Screening of combinatorial libraries and compounds of the invention also can be done with a calmodulin-dependent phosphodiesterase (CaMPDE) assay.
  • CaMPDE calmodulin-dependent phosphodiesterase
  • Compounds of the present invention can be useful as calmodulin antagonists.
  • Calmodulin (CaM) which is the major intracellular calcium receptor, is involved in many processes that are crucial to cellular viability.
  • Calmodulin is implicated in calcium- stimulated cell proliferation.
  • Calmodulin antagonists are, therefore, useful for treating conditions associated with increased cell proliferation, for example, cancer.
  • calmodulin antagonists such as compounds of the subject invention are useful both in vitro and in vivo for identifying the role of calmodulin in other biological processes.
  • the disadvantages of known antagonists such as trifluoperazine and N- (4-aminobutyl) - 5-chloro-2-naphthalenesulfonamide (W13) include their non-specificity and toxicity.
  • advantages of the combinatorial libraries and compounds of the subject invention as calmodulin antagonists include their reduced flexibility and ability to generate broader conformational space of interactive residues as compared to their linear counterparts.
  • an assay that identifies CaM antagonists is a CaMPDE assay.
  • samples are mixed with 50 ⁇ l of assay buffer (360 mM Tris, 360 mM Imidazole, 45 mM Mg(CH 3 COO) 2 , pH 7.5) and 10 ⁇ l of CaCl 2 (4.5 mM) to a final volume of 251 ⁇ l .
  • 25 ⁇ l of calmodulin stock solution (Boehringer Mannheim; 0.01 ⁇ g/ ⁇ l) is then added and the samples then sit at room temperature for 10 minutes.
  • trichloroacetic acid 55% in water
  • 80 ⁇ l of the resulting supernatants of each sample is transferred to a 96-well plate, with 2 wells each containing 80 ⁇ l of each sample.
  • 80 ⁇ l of ammonium molybdate (1.1% in 1. IN H 2 S0 4 ) is then added to all the wells, and the OD of each were determined at 730nm, with the values later subtracted to the final OD reading.
  • 16 ⁇ l of reducing agent 6g sodium bisulfite, 0.6g sodium sulfite and 125mg of l-amino-2-naphtol-4-sulfonic acid in 50ml of water
  • reducing agent 6g sodium bisulfite, 0.6g sodium sulfite and 125mg of l-amino-2-naphtol-4-sulfonic acid in 50ml of water
  • the percent inhibition of phosphodiesterase activity was determined by following a similar protocol as the CaMPDE assay described above, except not adding calmodulin to the sample mixture and calculating the percent inhibition by using as 0% inhibition a control reagent without any test samples and as 100% inhibition a control sample containing test samples and all reagents except cAMP.
  • MBHA 4-methylbenzhydrylamine
  • HOBt 1-hydroxybenzotriazole
  • DMSO dimethylsulfoxide
  • Boc tert-butoxycarbonyl
  • TFA trifluoroacetic acid
  • DIEA diisopropylethylamine
  • TMOF trimethylorthoformate
  • HATU azabenzotriazolyl-N, N, N' , N' -tetramethyluronium hexafluorophosphate
  • CDI carbonyldiimidazole
  • This example describes 68 variations at the R 5 position, the side chain of phenylalanine (Ph-CH 2 ) providing the R 6 position, 4-methoxyanilinocarbonyl at the R 3 position and hydrogen at the remaining R positions.
  • MBHA resin 1.3 meq/g
  • Tea-bag 60mm x 60mm, 65
  • the packet was washed with 5% DIEA/DCM (2 X 60 mL) in a 125 mL plastic bottle.
  • DMF 80 mL
  • Boc-phenylalanine 4.24g, 16 mmol
  • DIC 3.03g, 24 mmol
  • HOBt 2.16g, 16 mmol
  • the packet was washed alternately with DMF (80 mL) and MeOH (80 mL) for 3 cycles followed by DCM (80 mL) and MeOH (80 mL) .
  • the packet was dried in air for 2 hours.
  • the packet was shaken with 55% TFA/DCM (80 mL) at room temperature for 40 minutes and washed with DCM (3 X 80 mL) , 5% DIEA/DCM (2 X 80 mL) and MeOH (80 mL) .
  • the packet was shaken with a solution of morpholine (1.40 g, 16 mmol), DIC (3.03g, 24 mmol) and HOBt (2.16g, 16 mmol) in DMF (80 mL) for 24 hours.
  • the packet was washed alternately with DMF (80 mL) and MeOH (80 mL) for 3 cycles followed by DCM (80 mL) and MeOH (80 mL) .
  • the packet was dried in air overnight.
  • the packet was shaken with a 2.0 M solution of tin (II) chloride dihydrate in N-Methylpyrrolidinone (80 mL) for 24 hours at room temperature.
  • the packet was washed with DMF (4 X 80 mL) , 10% DIEA/DCM (4 X 80 mL) , MeOH, (2 X 80 mL) , DMF (80 mL) , MeOH (80 mL) , DCM (2 X 80 mL) and MeOH (2 X 80 mL) and dried in air overnight.
  • the packet was cut open and the resin was suspended in N-methylpyrrolidinone (30 mL) .
  • the suspension was distributed equally into 68 wells of a microtiter plate (2mL X 96) .
  • N-methylpyrrolidinone 100 ⁇ L X 1.0 M were added to each well.
  • the plate was tightly capped, shaken and incubated at 67° C for 48 hours.
  • the resin was washed alternately with DMF (3 X 1 mL/well) and MeOH (2 X 1 mL/well), DCM/t-BuOMe (50%, 2 X 1 mL/well) and MeOH (2 X 1 mL/well) .
  • the plate was dried in air overnight and under vacuum for 4 hours.
  • the plate was treated with gaseous HF at room temperature for 2 hours. After complete removal of HF under a nitrogen stream followed and by vacuum, the plate was extracted with AcOH (4 x 0.5 mL/well). The extraction solutions were lyophilized.
  • the 68 aldehydes used are as follows:
  • Example 1 describes the side chain of 18 different amino acids or diamines providing the R 6 position, 4-methoxyanilinocarbonyl at the R 3 position, phenyl at the R 5 position and hydrogen at the remaining R positions.
  • the 18 amino acids and diamines used were as follows :
  • glycine alanine beta-alanine gamma-aminobutyric acid epsilon-aminocaproic acid isoleucine glutamine methionine valine phenylglycine phenylalanine cyclohexylalanine 4-chloro-phenylalanine tryptophan lysine (TFA) arginine (Tos) ethylenediamine trans-1, 4-diaminocyclohexane
  • MBHA resin 1.3 meq/g
  • the packet was washed with 5% DIEA in DCM (2 X 20 mL) in a 40 mL plastic bottle, and shaken with a solution of carbonyldiimidazole (CDI) in DCM (0.5 M, 20 mL at room temperature for 2 hours. The solution was decanted.
  • the packet was quickly washed with DCM (2 X 20 mL) , and shaken with a solution of 1, 2-ethylenediamine or trans-1, 4-diaminocyclohexane in DCM (0.5 M, 20 mL) overnight.
  • the packet was washed alternately with dimethylformamide (DMF, 20 mL) and methanol (MeOH, 20 mL) for 4 cycles followed by washing with DCM and MeOH alternatively for 2 cycles and dried in air.
  • DMF dimethylformamide
  • MeOH MeOH
  • this example describes the side chain of beta-alanine providing the R 6 position, phenyl at the R 5 position, 28 different amines providing the R 3 position and hydrogen at the remaining R positions.
  • 6-aminoindazole beta-alanine ethyl ester cyclooctylamine cyclopropylamine dibenzylamine ethyl isonipecotate
  • This example describes methods for assaying binding to MC receptors.
  • HEK 293 cell lines were transfected with the human MC receptors hMCR- 1, hMCR-3, and hMCR-4 (Gantz et al., Biochem. Biophys. Res. Comm. 200:1214-1220 (1994); Gantz et al., J. Biol. Chem. 268:8246-8250 (1993); Gantz et al. J. Biol. Chem. 268:15174-15179 (1993); Haskell-Leuvano et al., Biochem. Biophys. Res. Comm.
  • hMCR-5 has been described previously (Franberg et al., Biochem. Biophys. Res. Commun. 236:489-492 (1997); Chowdhary et al.,
  • HEK 293 cells were maintained in DMEM, 25 mM HEPES, 2 mM glutamine, non-essential amino acids, vitamins, sodium pyruvate,
  • PBS phosphate buffered saline
  • Cells were suspended in PBS, 10% COSMIC CALF SERUM and 1 mM CaCl 2 .
  • Cell suspensions were prepared at a density of 2x10" cells/ml for HEK 293 cells expressing hMCR-3, hMCR-4 or hMCR-5, and lxlO 5 cells/ml for HEK 293 cells expressing hMCR-1.
  • Suspensions were placed in a water bath and allowed to warm to 37°C for 1 hr.
  • Binding assays were performed in a total volume of 250 ⁇ l for HEK 293 cells. Control and test compounds were dissolved in distilled water. 125 I-HP 467
  • GF/B filter plates were prepared by soaking for at least one hour in 5 mg/ml BSA and 10 mM CaCl 2 . Assays were filtered using a Brandel 96-well cell harvester (Brandel Inc.; Gaithersburg, MD) . The filters were washed four times with cold 50 mM Tris, pH 7.4, the filter plates were dehydrated for 2 hr and 35 ⁇ l of MICROSCINT was added to each well. Filter plates were counted using a Packard Topcount (Packard Instrument Co.) and data analyzed using GraphPad PRISM v2.0 (GraphPad Software Inc.; San Diego CA) and Microsoft EXCEL v5.0a (Microsoft Corp.; Redmond WA) .
  • Packard Topcount Packard Instrument Co.
  • THB 100 ul
  • Test compounds in DMSO and appropriate concentrations of DMSO were added to Growth/Solvent Controls at 0 time. Plates were read at 0 time at 570 nm in the Molecular Devices plate reader to obtain compounds correction factors for insoluble or colored compounds. Plates were read again at 4 hrs .
  • Color correct (O.D. 0 hr - Blank 0 hr)- (Solvent Control 0 hr - Blank 0 hr)
  • Rats are housed 2-3 per cage and are acclimated to the standard vivarium light cycle (12 hr. light, 12 hr. dark), rat chow and water for a least a week prior to testing. All experiments are performed between 9 a.m. and noon and rats are placed in cylindrical, clear plexiglass chambers during the 60 minute observation period. Mirrors are positioned below and to the sides of the chambers, to improve viewing.

Abstract

La présente invention se rapporte à de nouveaux composés tétracycliques dérivés de benzimidazole, représentés par la formule (I) dans laquelle R1 à R8 ont les significations données dans la description. Cette invention se rapporte en outre à des bibliothèques combinatoires contenant au moins deux de ces composés, ainsi qu'à des procédés de préparation de ces composés dérivés de benzimidazole.
PCT/US2000/020942 1999-09-21 2000-08-01 Derives de benzimidazole et bibliotheques combinatoires contenant ces derives WO2001021634A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP00950920A EP1214330A1 (fr) 1999-09-21 2000-08-01 Derives de benzimidazole et bibliotheques combinatoires contenant ces derives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40100499A 1999-09-21 1999-09-21
US09/401,004 1999-09-21

Publications (1)

Publication Number Publication Date
WO2001021634A1 true WO2001021634A1 (fr) 2001-03-29

Family

ID=23585870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/020942 WO2001021634A1 (fr) 1999-09-21 2000-08-01 Derives de benzimidazole et bibliotheques combinatoires contenant ces derives

Country Status (2)

Country Link
EP (1) EP1214330A1 (fr)
WO (1) WO2001021634A1 (fr)

Cited By (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
FR2851563A1 (fr) * 2003-02-26 2004-08-27 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US6825219B2 (en) 2001-11-09 2004-11-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
WO2005021537A1 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs de c-kit pyrazolyle-amidyle-benzimidazolyle n-substitues
WO2005021544A2 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
US7022714B2 (en) 2002-07-31 2006-04-04 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US7112600B1 (en) 1999-12-27 2006-09-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
WO2006060381A3 (fr) * 2004-12-01 2006-12-28 Osi Pharm Inc Inhibiteurs de c-kit benzimidazolyle n-substitues et banque de benzimidazoles combinatoire
US7189755B2 (en) 2001-08-10 2007-03-13 Palatin Technologies, Inc. Pyrrolidine melanocortin-specific compounds
WO2007043653A1 (fr) * 2005-10-13 2007-04-19 Taisho Pharmaceutical Co., Ltd. Derive de benzimidazole-5-carboxamide
WO2008000643A1 (fr) * 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Dérivés benzimidazole, procédé d'élaboration, utilisation comme agonistes vis-à-vis de fxr et préparations pharmaceutiques les contenant
WO2008052072A2 (fr) * 2006-10-24 2008-05-02 Acadia Pharmaceuticals Inc. Composés destinés au traitement de la douleur et procédés de dépistage à cet effet
US7384793B2 (en) 2001-04-11 2008-06-10 Rapid Biosensor Systems Limited Biological measurement system
US7425637B2 (en) 2002-03-13 2008-09-16 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
DE102007037579A1 (de) 2007-08-09 2009-02-19 Emc Microcollections Gmbh Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe
US7511145B2 (en) 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
US7550603B2 (en) 2005-04-11 2009-06-23 Abbott Laboratories Inc. 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
WO2009110542A1 (fr) * 2008-03-07 2009-09-11 住友化学株式会社 Composé anilide et son utilisation
US7595406B2 (en) 2005-11-15 2009-09-29 Abbott Laboratories Inc. Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
US7781596B1 (en) 1998-11-03 2010-08-24 Abbott Laboratories Substituted 2-phenylbenzimidazoles, the production thereof and their use
US7999117B2 (en) 2006-05-02 2011-08-16 Abbott Lab Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
US8071614B2 (en) 2007-10-12 2011-12-06 Astex Therapeutics Limited Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
US8076354B2 (en) 2007-10-12 2011-12-13 Astex Therapeutics Limited Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
US8093396B2 (en) 2009-01-19 2012-01-10 Abbott Laboratories Benzthiazole inhibitors of poly(ADP-ribose)polymerase
US8435988B2 (en) 2010-10-06 2013-05-07 Glaxosmithkline Llc Benzimidazole derivatives as P13 kinase inhibitors
US8481531B2 (en) 2009-04-15 2013-07-09 Astex Therapeutics Ltd Bicyclic heterocyclyl derivatives as FGFR kinase inhibitors for therapeutic use
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
US8722687B2 (en) 2009-04-15 2014-05-13 Astex Therapeutics Ltd Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy
US8796244B2 (en) 2008-06-13 2014-08-05 Astex Therapeutics Ltd Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
EP3389785A4 (fr) * 2015-12-16 2019-05-08 Merck Sharp & Dohme Corp. Benzimidazoles et indoles utilisés comme inhibiteurs de taro
WO2020033514A1 (fr) * 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Inhibiteurs benzimidazoles d'enzymes pad
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107311933B (zh) * 2017-06-28 2020-12-22 中国人民解放军军事医学科学院毒物药物研究所 一类苯并咪唑衍生物，及其制备方法和用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010219A1 (fr) * 1995-09-11 1997-03-20 Fujisawa Pharmaceutical Co., Ltd. Derives benzimidazoliques, et leur utilisation dans la prevention et le traitement de maladies osseuses
WO1999040072A1 (fr) * 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg Heterocycles benzo condenses a 5 chainons utilises comme agents antithrombotiques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010219A1 (fr) * 1995-09-11 1997-03-20 Fujisawa Pharmaceutical Co., Ltd. Derives benzimidazoliques, et leur utilisation dans la prevention et le traitement de maladies osseuses
WO1999040072A1 (fr) * 1998-02-03 1999-08-12 Boehringer Ingelheim Pharma Kg Heterocycles benzo condenses a 5 chainons utilises comme agents antithrombotiques

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781596B1 (en) 1998-11-03 2010-08-24 Abbott Laboratories Substituted 2-phenylbenzimidazoles, the production thereof and their use
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US7285551B2 (en) 1999-12-27 2007-10-23 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US7112600B1 (en) 1999-12-27 2006-09-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US8030088B2 (en) 2001-04-11 2011-10-04 Rapid Biosensor Systems Limited Sample collection apparatus
US7384793B2 (en) 2001-04-11 2008-06-10 Rapid Biosensor Systems Limited Biological measurement system
US7189755B2 (en) 2001-08-10 2007-03-13 Palatin Technologies, Inc. Pyrrolidine melanocortin-specific compounds
US7601753B2 (en) 2001-08-10 2009-10-13 Palatin Technologies, Inc. Pyrrolidine melanocortin-specific compounds
US7326707B2 (en) 2001-08-10 2008-02-05 Palatin Technologies Incorporated Bicyclic melanocortin-specific compounds
US6825219B2 (en) 2001-11-09 2004-11-30 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
US8003805B2 (en) 2002-03-13 2011-08-23 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7425637B2 (en) 2002-03-13 2008-09-16 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US7973170B2 (en) 2002-03-13 2011-07-05 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US8193229B2 (en) 2002-03-13 2012-06-05 Array Biopharma Inc. Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors
US8513293B2 (en) 2002-03-13 2013-08-20 Array Biopharma Inc. Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal
US8193230B2 (en) 2002-03-13 2012-06-05 Array Biopharma Inc. Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
US8178693B2 (en) 2002-03-13 2012-05-15 Array Biopharma Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
US8193231B2 (en) 2002-03-13 2012-06-05 Array Biopharma Inc. Compositions comprising N3 alkylated benzimidazole derivatives as MEK inhibitors and methods of use thereof
US7022714B2 (en) 2002-07-31 2006-04-04 Euro-Celtique S.A. Aryl substituted benzimidazoles and their use as sodium channel blockers
US7138420B2 (en) 2002-08-08 2006-11-21 Boehringer Ingelheim Pharmaceuticals Inc. Substituted benzimidazole compounds
WO2004075823A3 (fr) * 2003-02-26 2004-10-07 Sod Conseils Rech Applic Derives de benzimidazole et d’imidazo-pyridine ayant une addinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament
JP2006519214A (ja) * 2003-02-26 2006-08-24 ソシエテ ド コンセイユ ド ルシェルシェ エ ダアップリカーション シャンティフィック（エス．セー．エール．アー．エス．） 新規ベンゾイミダゾール及びイミダゾピリジン誘導体並びにこれらの医薬としての使用
KR101074579B1 (ko) 2003-02-26 2011-10-17 입센 파마 에스.에이.에스 신규 벤즈이미다졸 및 이미다조피리딘 유도체 및 그의의약으로서 용도
FR2851563A1 (fr) * 2003-02-26 2004-08-27 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
WO2004075823A2 (fr) * 2003-02-26 2004-09-10 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derives de benzimidazole et d’imidazo-pyridine ayant une addinite pour les recepteurs des melanocortines et leur utilisation en tant que medicament
AU2004216427B2 (en) * 2003-02-26 2009-06-25 Ipsen Pharma S.A.S. Novel benzimidazole and imidazopyridine derivatives and use thereof as a medicament
JP4714673B2 (ja) * 2003-02-26 2011-06-29 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ 新規ベンゾイミダゾール及びイミダゾピリジン誘導体並びにこれらの医薬としての使用
US7816539B2 (en) 2003-02-26 2010-10-19 Ipsen Pharma S.A.S. Derivatives of benzimidazole and imidazo-pyridine and their use as medicaments
US7511145B2 (en) 2003-08-01 2009-03-31 Genelabs Technologies, Inc. Bicyclic heteroaryl derivatives
US7442709B2 (en) 2003-08-21 2008-10-28 Osi Pharmaceuticals, Inc. N3-substituted imidazopyridine c-Kit inhibitors
US7767673B2 (en) 2003-08-21 2010-08-03 Osi Pharmaceuticals, Inc. N-substituted imidazopyridine c-Kit inhibitors
WO2005021537A1 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs de c-kit pyrazolyle-amidyle-benzimidazolyle n-substitues
WO2005021544A2 (fr) 2003-08-21 2005-03-10 Osi Pharmaceuticals, Inc. Inhibiteurs d'un ensemble d'imidazopyridine c n3 substitue
WO2006060381A3 (fr) * 2004-12-01 2006-12-28 Osi Pharm Inc Inhibiteurs de c-kit benzimidazolyle n-substitues et banque de benzimidazoles combinatoire
US8217070B2 (en) 2005-04-11 2012-07-10 Abbott Laboratories 2-substituted-1H-benzimidazole-4-carboxamides are PARP inhibitors
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
US7550603B2 (en) 2005-04-11 2009-06-23 Abbott Laboratories Inc. 1H-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent PARP inhibitors
WO2007043653A1 (fr) * 2005-10-13 2007-04-19 Taisho Pharmaceutical Co., Ltd. Derive de benzimidazole-5-carboxamide
US7595406B2 (en) 2005-11-15 2009-09-29 Abbott Laboratories Inc. Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
US7999117B2 (en) 2006-05-02 2011-08-16 Abbott Lab Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors
WO2008000643A1 (fr) * 2006-06-29 2008-01-03 F. Hoffmann-La Roche Ag Dérivés benzimidazole, procédé d'élaboration, utilisation comme agonistes vis-à-vis de fxr et préparations pharmaceutiques les contenant
US7645785B2 (en) 2006-06-29 2010-01-12 Hoffmann-La Roche Inc. Benzimidazole derivatives
WO2008052072A3 (fr) * 2006-10-24 2008-11-13 Acadia Pharm Inc Composés destinés au traitement de la douleur et procédés de dépistage à cet effet
WO2008052072A2 (fr) * 2006-10-24 2008-05-02 Acadia Pharmaceuticals Inc. Composés destinés au traitement de la douleur et procédés de dépistage à cet effet
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
US8895745B2 (en) 2006-12-22 2014-11-25 Astex Therapeutics Limited Bicyclic heterocyclic compounds as FGFR inhibitors
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
DE102007037579A1 (de) 2007-08-09 2009-02-19 Emc Microcollections Gmbh Neue Benzimidazol-2-yl-alkylamine und ihre Anwendung als mikrobizide Wirkstoffe
US8076354B2 (en) 2007-10-12 2011-12-13 Astex Therapeutics Limited Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
US8859583B2 (en) 2007-10-12 2014-10-14 Astex Therapeutics Limited Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
US8071614B2 (en) 2007-10-12 2011-12-06 Astex Therapeutics Limited Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
US8859582B2 (en) 2007-10-12 2014-10-14 Astex Therapeutics Limited Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors
WO2009110542A1 (fr) * 2008-03-07 2009-09-11 住友化学株式会社 Composé anilide et son utilisation
US8796244B2 (en) 2008-06-13 2014-08-05 Astex Therapeutics Ltd Imidazopyridine derivatives as inhibitors of receptor tyrosine kinases
US8093396B2 (en) 2009-01-19 2012-01-10 Abbott Laboratories Benzthiazole inhibitors of poly(ADP-ribose)polymerase
US8481531B2 (en) 2009-04-15 2013-07-09 Astex Therapeutics Ltd Bicyclic heterocyclyl derivatives as FGFR kinase inhibitors for therapeutic use
US8722687B2 (en) 2009-04-15 2014-05-13 Astex Therapeutics Ltd Imidazo [1,2-A]pyridine derivatives as FGFR kinase inhibitors for use in therapy
US9062003B2 (en) 2010-10-06 2015-06-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8865912B2 (en) 2010-10-06 2014-10-21 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8541411B2 (en) 2010-10-06 2013-09-24 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8435988B2 (en) 2010-10-06 2013-05-07 Glaxosmithkline Llc Benzimidazole derivatives as P13 kinase inhibitors
US9156797B2 (en) 2010-10-06 2015-10-13 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US9872860B2 (en) 2010-10-06 2018-01-23 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10314845B2 (en) 2010-10-06 2019-06-11 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US8674090B2 (en) 2010-10-06 2014-03-18 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US10660898B2 (en) 2010-10-06 2020-05-26 Glaxosmithkline Llc Benzimidazole derivatives as PI3 kinase inhibitors
US11141403B2 (en) 2015-12-16 2021-10-12 Merck Sharp & Dohme Corp Benzimidazoles and indoles as taro inhibitors
EP3389785A4 (fr) * 2015-12-16 2019-05-08 Merck Sharp & Dohme Corp. Benzimidazoles et indoles utilisés comme inhibiteurs de taro
US11752128B2 (en) 2015-12-16 2023-09-12 Merck Sharp & Dohme Corporation Benzimidazoles and indoles as taro inhibitors
WO2020033514A1 (fr) * 2018-08-08 2020-02-13 Bristol-Myers Squibb Company Inhibiteurs benzimidazoles d'enzymes pad
JP2021534104A (ja) * 2018-08-08 2021-12-09 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Ｐａｄ酵素のベンズイミダゾール阻害剤
CN112789087A (zh) * 2018-08-08 2021-05-11 百时美施贵宝公司 Pad酶的苯并咪唑抑制剂
JP7434281B2 (ja) 2018-08-08 2024-02-20 ブリストル－マイヤーズ スクイブ カンパニー Ｐａｄ酵素のベンズイミダゾール阻害剤
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11944622B2 (en) 2018-10-05 2024-04-02 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity

Also Published As

Publication number Publication date
EP1214330A1 (fr) 2002-06-19

Similar Documents

Publication Publication Date Title
WO2001021634A1 (fr) Derives de benzimidazole et bibliotheques combinatoires contenant ces derives
US6677452B1 (en) Pyridine carboxamide or sulfonamide derivatives and combinatorial libraries thereof
US6143895A (en) Quinoline derivatives and quinoline combinatorial libraries
US6515122B1 (en) Tetracyclic benzimidazole derivatives and combinatorial libraries thereof
US6458789B1 (en) 2-aminopyridine derivatives and combinatorial libraries thereof
WO1998002741A9 (fr) Banques de combinaisons de quinoleine et de derives de quinoleine
WO2002012166A2 (fr) Ligands de recepteurs de melanocortines derives de triamines et procedes d'utilisation desdits ligands
US5856107A (en) Combinatorial libraries of imidazol-pyrido-indole and imidazol-pyrido-benzothiophene derivatives, methods of making the libraries and compounds therein
WO2000025768A1 (fr) Derives oxadiazole, thiadiazole et triazole et bibliotheques combinatoires contenant ces derives
AU4481800A (en) Diketodiazacyclic compounds, diazacyclic compounds and combinatorial libraries thereof
US6660858B2 (en) 2-aminobenzoxazole derivatives and combinatorial libraries thereof
US20030171588A1 (en) 1,2-disubstituted-6-oxo-3-phenyl-piperidine-3-carboxamides and combinatorial libraries thereof
US20030232994A1 (en) Bicyclic thiophene derivatives and combinatorial libraries thereof
EP1150565A1 (fr) Derives de thiazole et leurs banques combinatoires
US5786448A (en) Combinatorial libraries of cyclic urea and cyclic thiourea derivatives and compounds therein
US6452009B1 (en) 4-unsubstituted dihydroisoquinolinone derivatives and combinatorial libraries thereof
EP1301512A2 (fr) Derives d'hydantoine bicycliques et bibliotheques combinatoires de ces derniers
US6362342B1 (en) Triazole compounds and methods of making same
US20040102629A1 (en) Thioquinazolinone derivatives and combinatorial libraries thereof
US20040010036A1 (en) N,N, -Substituted s-Aryl-Isothioureas, N,N,N, -Substituted s-Aryl-Isothioureas and combinatorial libraries thereof
US6359144B1 (en) Combinatorial libraries of bicyclic guanidine derivatives and compounds therein
WO1998034113A1 (fr) Banques combinatoires de derives bicycliques de guanidine et composes contenus dans de telles banques

Legal Events

Date Code Title Description
AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000950920

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000950920

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000950920

Country of ref document: EP